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1. Introduction 
1.1 Cancer 
The hallmarks of cancer comprise six biological capabilities acquired during the 
multistep development of human tumors (Hanahan and Weinberg, 2000). The 
hallmarks constitute an organizing principle for rationalizing the complexities of 
neoplastic disease (Figure I). They include sustaining proliferative signaling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis. Underlying these lineaments are 
genome instability, which generates the genetic diversity that expedites their 
acquisition, and inflammation, which fosters multiple hallmark functions (Hanahan 
and Weinberg, 2011).  
 
Conceptual progress in the last decade has added two emerging lineaments of potential 
generality to this list: reprogramming of energy metabolism and evading immune 
destruction (Pisanti et al., 2013). In addition to cancer cells, tumors exhibit another 
dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells 
that contribute to the acquisition of cancer traits by creating the tumor 
microenvironment (Hanahan and Weinberg, 2011). Recognition of the widespread 
applicability of these concepts will increasingly affect the development of new means 
to treat human cancer. 
 
Now the importance of lipid mediators in cancer progression is raised after the addition 
of reprogramming of energy metabolism, occurs in tumor cells, to the list of hallmarks 
(Hanahan and Weinberg, 2011). Besides switching from oxidative to glycolytic 
metabolism, tumor cells require anabolic processes to augment the synthesis of 
proteins, nucleic acids, and lipids. Whereas most tissues besides the liver, adipose 
tissue, and breast acquire fatty acids primarily from dietary sources, tumor cells 
increase de novo fatty acid synthesis to produce membrane building blocks 
(phosphoglycerides, sterols, and sphingolipids), to store energy (triacylglycerides), and 
to contribute to energy homeostasis (Santos and Schulze, 2012). In addition, lipid 
moieties are necessary to generate lipid messengers, such as sphingolipids, lysolipids, 
and arachidonic-acid-derived endocannabinoids, to modulate important cellular 
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processes from proliferation and apoptosis to neoplastic transformation, tumor growth, 
and progression. Therefore, better knowledge of the physiological contribution or 
deregulation of these signaling systems in tumor growth and progression, especially in 
terms of mechanistic insights into the signal transduction components involved, could 
lead to the disclosure of novel therapeutic targets and tools like the endocannabinoid 
system (Pisanti et al., 2013). 
 
The 2014 World Cancer Report, produced by the WHO's specialized cancer agency, 
predicts the rise of cancer cases from an estimated 14 million in 2012 to 22 million 
annually within two decades. Over the same period, cancer deaths are tipped to rise 
from 8.2 million a year to 13 million annually. 
 
Breast cancer is the leading cause of female cancer-related mortality, with more than 
458000 deaths estimated worldwide in 2008 (Ferlay et al., 2010). The incidence of 
breast cancer varies worldwide, with rates in North America and North and West 
Europe higher than those in South America and South Europe, with the lowest rates in 
Africa and Asia (Ferlay et al., 2010). Although incidence remains much lower in Arab 
populations compared with those from Europe and the USA, rates are increasing 
steadily (El Saghir et al., 2007). Although the rates of mortality have declined mainly 
due to adjuvant systemic therapy and earlier detection by palpation and mammograms, 
certain breast tumors remain resistant to conventional therapies (Chouchane et al., 
2013). In addition, current treatments have side effects that substantially affect the 
patients’ quality of life (DeSantis et al., 2011). It is therefore obvious that new 
therapeutic strategies are needed for the management of this condition.  
 
Brain tumors are the second and fifth leading causes of cancer-related deaths in males 
and females ages 20 to 39, respectively (Jemal et al., 2009). Among the various brain 
tumors which affect humans, glioblastoma are the most common (1/50,000 
persons/year), malign (mortality near 100%) and fastest evolving (life expectation of 
weeks/months after diagnosis). Nowadays treatment of glioblastoma is generally 
ineffective or merely palliative, and implies such therapies as surgery, radiotherapy, 
chemotherapy and immunotherapy (Torres et al., 2011). Additionally gene therapy is 
Introduction 
P a g e | 3   
 
beginning to be used as an experimental treatment for glioblastomas, although so far it 
has produced few positive results (Parolaro and Massi, 2008). The unlikelihood of 
success of these therapeutic approaches can be further complicated by factors such as 
the rapid growth, great heterogeneity, high level of infiltration and an extreme 
resistance to chemotherapy shown by glioblastomas (Torres et al., 2011). It would 
therefore be highly desirable to develop novel therapeutic alternatives for the treatment 
of brain tumors.  
 
 
Figure I. The hallmarks of cancer (Adopted from Hanahan and Weinberg, 2000) 
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1.2 Role of angiogenesis in cancer 
 
1.2.1 Introduction 
The generation of new capillaries from pre-existing blood vessels is defined as 
angiogenesis (Folkman, 1971). Angiogenesis process takes place physiologically 
during embryogenesis and in the adult, for example in the female reproductive system 
and wound healing. Additionally angiogenesis occurs in pathological conditions such as 
cancer, macular degeneration, psoriasis and rheumatoid arthritis (Klagsbrun and 
Moses, 1999). 
 
Angiogenesis and tumor progression are closely linked as tumor cells depend on 
angiogenesis to safeguard their oxygen and nutrients supply for their growth and 
expansion. Indeed several studies on tumor development showed that an alteration in 
the blood supply can noticeably affect the tumor growth and its metastasis (Lutsenko et 
al, 2003). 
 
The growth of a tumor is fed initially by nearby blood vessels. Once a certain tumor 
size is reached (1-2 mm in diameter), these blood vessels are no longer sufficient and 
new blood vessels are required to continue growth (Folkman, 1972). The ability of a 
tumor to induce the formation of new vasculature has been termed the “angiogenic 
switch” and can occur at different stages of the tumor progression pathway depending 
on the type of tumor and the environment (Bergers and Benjamin, 2003) (Figure II). 
Acquisition of the angiogenic phenotype can result from genetic changes or local 
environmental changes that lead to the activation of endothelial cells.  
One way for a tumor to activate endothelial cells is through the secretion of pro-
angiogenic growth factors, which then bind to receptors on nearby dormant endothelial 
cells that line the interior of vessels. The growth factors can also act on more distant 
cells recruiting bone marrow derived precursor endothelial cells and circulating 
endothelial cells to migrate to the tumor vasculature (Bergers and Benjamin, 2003; 
Carmeliet, 2003). The pro-angiogenic growth factors may be overexpressed because of 
genetic alterations of oncogenes and tumor suppressors, or in response to the reduced 
availability of oxygen (hypoxia).  
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Tumor cell expression of many of the angiogenic factors, including vascular endothelial 
growth factor (VEGF), is regulated by hypoxia through the transcription factor hypoxia 
inducible factor (HIF) (Pugh and Ratcliffe, 2003). As the tumor cells proliferate, 
oxygen becomes depleted and a hypoxic microenvironment occurs within the tumor. 
HIF is degraded in the presence of oxygen, and therefore formation of hypoxic 
conditions leads to HIF activation and transcription of target genes. The strongest 
activation of HIF results from hypoxia, but several other factors can contribute to the 
increased expression and activity of HIF, including growth factors and cytokines such 
as tumor necrosis factor-α (TNF-α) (Hellwig-Bürgel et al., 1999), interleukin-1β (IL-
1β) (Stiehl et al., 2002) epidermal growth factor (EGF) (Zhong et al., 2000; Jiang et 
al., 2001) and insulin-like growth factor-1 (IGF-1) (Fukuda et al., 2002) which lead to 
increased cell signaling and activity of endothelial cells. Along similar lines, oncogenes 
that trigger increased expression of growth factors and overactive signaling pathways 
can increase HIF expression and activity. 
 
1.2.2 Vascular endothelial growth factor (VEGF) 
VEGF is also known as vascular permeability factor (VPF) because it was initially 
recognized for its ability to increase the microvascular permeability (Dvorak et al., 
1999). It was initially identified in 1983 as a tumor derived factor capable of increasing 
vascular permeability (Senger et al., 1983).  
VEGF is essential for normal vessel development in the embryo, where it promotes the 
differentiation, proliferation and survival of endothelial cells and expansion of the 
vascular tree. Beside its function during embryogenesis, VEGF also plays a crucial role 
in angiogenesis in the adult. VEGF was detected in the ovary during corpus luteum 
formation (Ferrara et al., 1998) and in the uterus during growth of endometrial vessels 
and at the side of embryo implantation. Also, high VEGF levels were detected during 
the proliferative phase of wound healing (Nissen et al., 1998). VEGF is equally 
detectable in areas where endothelial cells are quiescent, such as heart, lung, and brain, 
pointing to the role of VEGF as a survival factor (Veikkola and Alitlo, 1999). Finally, 
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VEGF is thought to play a role in several human cancers, diabetic retinopathy, 
rheumatoid arthritis, and atherosclerosis (Inoue et al., 1998). 
In addition to the hypoxia, several cytokines, growth factors and their receptors play a 
significant role as VEGF-gene transcription regulators. These include the EGF and its 
receptor EGFR; the IGF and its receptor IGFR; the fibroblast growth factor (FGF), both 
acidic and basic isoforms; transforming growth factor (TGF), both alpha and beta 
isoforms; TNF-α; placental derived endothelial cell growth factor (PD-ECGF); and 
angiopoietin and prostaglandins. Many oncogenes and tumor suppressor genes have 
also been reported to influence angiogenesis by direct or indirect up-regulation of 
VEGF (Vogelstein and Kinzler, 2004). 
The angiogenic effects of VEGF ligands are mediated by their binding to different 
receptors. The main VEGF receptors are VEGFR-1, VEGFR-2, and VEGFR-3. 
VEGFR-2 activation is considered most closely associated with signals for 
proliferation, migration, permeability and tube formation (Millauer et al., 1994), while 
activation of VEGFR-1 is more closely associated with monocyte migration (Zhu and 
Witte, 1999). Although VEGFR-2 is highly expressed in vascular endothelial 
progenitors in early emryogenesis, VEGFR-2 expression declines during later stages of 
vascular development to become up-regulated under conditions of pathological 
angiogenesis such as in tumors (Matsumoto and Claesson-Welsh, 2001).  
VEGF is ubiquitously expressed in almost all human tumors studied to date. Higher 
levels of expression of VEGF/VEGFR  have been associated with increased tumor 
vascularity, rapid growth, invasion, metastasis, and poor clinical prognosis in tumors of 
the bladder (Crew et al., 1997), brain (Vaquero et al., 2000), breast (Linderholm et al., 
2000), colon (Tokunaga et al., 1998), lung (Fontanini et al., 2002), ovary (Fujimoto et 
al., 1998), neuroblastoma (Davidoff et al., 2001), and gliomas (Millauer et al., 1994). 
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Figure II. The angiogenic switch:  
(a) Almost all tumors start growing as avascular nodules (dormant) until they reach a steady-state level 
of proliferating and apoptotic cells. The angiogenic switch starts when tumor needs the oxygen and 
nutrients in order to grow. (b) The switch begins with vessel dilation and perivascular detachment, then 
(c) Angiogenic sprouting starts, (d) The new vessels are formed and start to mature; the recruitment of 
perivascular cells takes place, (e) The newly formed blood vessels will specifically feed hypoxic and 
necrotic areas of the tumor to provide it with essential nutrients and oxygen so the tumor can grow. 
(Adopted from Bergers et al., 2003) 
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1.3 Role of transforming growth factor β (TGF-β) in cancer 
TGF-β plays a dual and paradoxical role in cancer (Katz et al., 2013). On one hand it 
acts as a tumor suppressor during the early phase of carcinogenesis, inhibiting cell 
growth and inducing apoptosis or differentiation (Derynck et al., 2001). On the other 
hand, cancer cells that have lost this inhibitory growth response exploit the ability of 
TGF-β to modulate processes such as cell invasion, angiogenesis, immune regulation, 
or interactions between tumor cells and their microenvironment that make them more 
malignant (Derynck et al., 2001). The tumor suppressor and tumor promoting effect of 
TGF-β may be exerted on the tumor cells themselves or indirectly by taking the 
advantage of the interactions between the tumor and stroma (Stover et al., 2007).  
 
Some cancer cells evade the tumor suppressor effects of TGF-β by accumulating 
inactivating mutations in the TGF-β receptors and SMAD proteins (Levy and Hill, 
2006). This is particularly true for subsets of colorectal, pancreatic, ovarian, gastric, and 
head and neck carcinomas. However, the core components of TGF-β signaling remain 
intact in majority of tumors (i.e., breast and prostate carcinomas, melanomas, gliomas 
and hematopoietic neoplasias). Cells within these tumors avoid the tumor suppressor 
activity of TGF-β by a variety of mechanisms that are not fully understood and which 
lead to the loss of the TGF-β anti-proliferative response (Seoane, 2006).  
 
Other alterations that may contribute to the loss of the anti-proliferative response of 
TGF-β in gliomas are phosphatidylinositol-3-kinase (PI3K) hyperactivation or 
mutational inactivation of the retinoblastoma (RB) locus (Jennings and Pietenpol, 
1998). However, in many tumors that preserve an intact TGF-β signaling pathway the 
precise mechanisms leading to the loss of the TGF-β cytostatic response is unknown.  
 
TGF-β1, which is the most extensively characterized, is secreted as a biologically 
inactive protein complex consisting of the TGF-β1 homodimer and the latency 
associated protein (LAP) which is associated with the latent TGF-β1 binding protein 
(LTBP) glycoprotein via a disulfide bond (Rifkin, 2005). Activated TGF-β ligands 
initiate their cellular effects by binding to high affinity cell surface receptors, including 
type I (activin like kinase (ALK) 1-7) and type II TGF-β superfamily receptors (ActR-
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II, ActR-IIB, BMPRII, AMHRII, and TβR-II) (Figure III). The type II receptors are 
constitutively active serine/threonine kinases, with ligand binding resulting in 
conformational changes that induces recruitment and complex formation with an 
appropriate type I receptor forming a heteromeric complex (Figure III) (Samad et al., 
2005). The type II receptor then phosphorylates the type I receptor in the glycine serine 
rich domain, activating its serine/threonine kinase activity (De caestecker, 2004). The 
activated type I receptors mediate their cellular effects through interaction and 
phosphorylation of SMAD proteins, a family of conserved transcription factors, as 
summarized in Figure III.  
 
 
Figure III. The transforming growth factor β (TGF-β) /SMAD pathway:  
Binding of a the TGF-β family member to its type II receptor (1) in concert with a type I receptor (2) 
leads to formation of a receptor complex (3) and phosphorylation of the type I receptor (4). Thus 
activated, the type I receptor subsequently phosphorylates a receptor-regulated SMAD (R-SMAD) (5), 
allowing this protein to associate with SMAD4 (6) and move into the nucleus (7). In the nucleus, the 
SMAD complex associates with a DNA-binding partner, such as Fast-1 (8), and this complex binds to 
specific enhancers in targets genes (9), activating transcription. (Adopted from Massagué, 1998) 
 
Introduction 
P a g e | 10   
 
1.4 Role of endoglin in cancer (CD-105) 
CD-105 is an auxiliary membrane receptor of TGF-β that interacts with type I and type 
II TGF-β receptors and modulates TGF-β signaling. Mutations in endoglin are involved 
in Hereditary Hemorrhagic Telangiectasia type I, a disorder characterized by cutaneous 
telangiectasias, epistaxis (nosebleeds) and major arteriovenous shunts, mainly in liver 
and lung (Pérez-Gómez et al, 2010).  
 
CD-105 is overexpressed in tumor-associated endothelium, which modulates 
angiogenesis and facilitates metastasis. This finding implies that CD-105 has a role in 
tumor progression through its effects on the stroma (Chakhachiro et al., 2013). 
Expression of CD-105 by malignant cells also has been documented in human sarcoma, 
metastatic melanoma and breast tumor cells (Fonsatti et al., 2001; Postiglione et al., 
2005; Oxmann et al., 2008). In a recent study, Pérez-Gómez et al (2010) suggested that 
changes in CD-105 expression levels in tumor cells contribute to deregulation of TGF-β 
dependent and TGF-β independent signaling pathways and malignant progression. 
Based on these preclinical data, antibodies specific for CD-105 have been developed 
and are currently being used in phase I and II clinical trials (Rosen et al., 2012). 
 
CD-105 expression is necessary for the activation of ALK1 mediated endothelial cell 
stimulation. ALK1 activation causes an increase in endothelial cell proliferation and 
migration as well as transcription of the pro-angiogenic genes including, CD-105 itself 
(Bertolino et al., 2005; Blanco et al., 2005). In contrast, ALK5 signaling induces 
endothelial cell quiescence by inhibiting proliferation and migration and increases 
expression of maturation-specific genes, such as fibronectin, connexin-37, α3/β1 
integrin, and plasminogen activator inhibitor-1 (Bertolino et al., 2005; Lebrin et al., 
2005; Bobik, 2006). ALK5 signaling on endothelial cells also promotes the recruitment 
and differentiation of vascular smooth muscle cells during vessel formation (Bertolino 
et al., 2005). ALK5 is the predominant mediator of TGF-β signaling in quiescent 
endothelial cells, but during angiogenesis, ALK1 is preferentially activated (Bertolino 
et al., 2005; Lebrin et al., 2005).  
In addition, the complete absence of ALK5 in cells causes a decrease in ALK1 
signaling, indicating that the presence of ALK5 is also necessary for signaling via 
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ALK1 (Lebrin et al., 2004). TGF-β signaling in the presence of CD-105 causes an 
activation of ALK1-associated SMAD-1/5 proteins (Figure IV) as well as negative 
regulation of the ALK5-associated SMAD-2/3 proteins (Duff et al., 2003; Santibanez 
et al., 2007).  
 
Loss of the inhibitory function of TGF-β1 has been noted in cells with up-regulated CD-
105, causing the tumor cells to be resistant to the inhibitory effects of TGF-β 
(Warrington et al., 2005). When CD-105 expression was reduced by an antisense 
approach, the inhibitory effects of TGF-β on cells proliferation, migration were 
heightened (Li et al., 2000). These effects were mediated by ALK5 signaling (Figure 
IV), emphasizing that CD-105 is a negative regulator of ALK5 activity (Lebrin et al., 
2005). Stable transfection of endothelial cells with small interfering RNA (siRNA) to 
CD-105 also enhanced the ability of TGF-β to suppress growth and migration (Lebrin 
et al., 2004; Warrington et al., 2005). Furthermore, when CD-105 siRNA-transfected 
cells were irradiated in-vitro, they showed a decrease in cell viability, with elevation of 
p53 (pro-apoptotic) and reduction of bcl-2 (anti-apoptotic) levels compared with mock-
transfected cells (Warrington et al., 2005).  
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Figure IV. A schematic hypothetical role of CD-105 in TGF-β/ALK-1 and TGF-β/ALK-5 signaling 
pathways in endothelial cells (ECs): 
In endothelial cells, TGF-β can activate two types I receptor pathways with opposite effects: ALK-5 
inducing SMAD 2/3 phosphorylation and ALK-1 promoting SMAD 1/5 phosphorylation. CD-105 binds 
TGF-β by associating with TGF-β signaling receptors type II (TβR-II). This association results in an 
altered phosphorylation state of TβR-II promoting endothelial cells proliferation via TGF-β/ALK-1 
signaling pathway and inducing an indirect inhibition of ALK-5 signaling pathway. Upon activation, 
phosphorylated SMADs form heteromeric complexes with the common mediator SMAD 4, which in the 
nucleus act as transcription factor complexes regulating the transcriptional activity of target genes. 
(Adopted from Fonsatti et al., 2010) 
Abbreviations: ALK, activin receptor like kinase (type of TGF-β receptor I); ECs, endothelial cells; 
TGF-β, transforming growth factor beta; TβR-II, TGF-β receptor II.  
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1.5 Role of extracellular signal regulated kinases in cancer 
The extracellular signal regulated kinases (ERK1/2) are ubiquitous regulators of 
multiple cellular processes such as proliferation, differentiation, survival, and 
transformation (Deschenes-Simard et al., 2014). These kinases are the last components 
of a signaling module composed of the small GTPase RAS and the protein kinases RAF 
and MEK1/2 (Karnoub and Weinberg, 2008). With an overall mutation incidence of 
up to 30% in human cancer, mutant RAS is among the most common human oncogenes 
(Schubbert et al., 2007). RAF mutations are also frequent, particularly in melanoma 
(Maurer et al, 2011), but MEK mutations are rare and ERK mutations have never been 
reported as drivers in human cancers. Nevertheless, current thinking proposes that both 
RAS and RAF oncogenes promote human cancers by activating the ERK kinases 
(Schubbert et al., 2007). Consistent with this idea is the fact that ERK kinases 
positively regulate the cell cycle by increasing the availability of building blocks for 
cell growth, by stimulating the cyclin-dependent kinase (CDK)–cyclin complexes 
required for cell-cycle progression, and by preventing cell death (Deschenes-Simard et 
al., 2014). In addition, deregulated nuclear accumulation of activated ERKs (p-ERK) 
can lead to genomic instability and subsequent tumor progression (Duhamel et al., 
2012). On the other hand, many reports indicate that the ERK kinases may trigger 
tumor suppressor pathways as well (Bric et al., 2009; Deschenes-Simard et al., 2013) 
and that this activity depends on the strength of their activation (Deschenes-Simard et 
al., 2013). Hence, the role of ERK kinases in human cancers appears to be context 
dependent and more complex than originally suspected, reflecting its involvement in 
both oncogenesis and tumor suppression (Deschenes-Simard et al., 2014). Clinical 
studies indicate a variable association between ERK activation and human cancers, 
consistent with either an oncogenic or a tumor-suppressing role. Consequently, ERK 
activation in human cancers has been linked to either good or bad prognosis 
(Deschenes-Simard et al., 2014). Therefore, it is unclear whether sustained ERK 
hyperphosphorylation is an obligate prerequisite of cancer initiation or progression 
despite activated oncogenes upstream of the pathway.  
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1.6 The endocannabinoid system 
 
1.6.1 Introduction 
Cannabinoid refers to a group of chemicals naturally found in the marijuana plant 
Cannabis sativa and includes compounds that are either structurally or 
pharmacologically similar to Δ9-tetrahydrocannabinol (THC) or those that bind to the 
cannabinoid receptors. There are three types of cannabinoids: 1) plant-derived 
cannabinoids such as THC and cannabidiol occur uniquely in the cannabis plant; 2) 
endogenous cannabinoids also known as endocannabinoids such as N-
arachidonoylethanolamine or anandamide (AEA) and 2-arachidonoylglycerol (2-AG) 
are produced in the bodies of humans and animals; and 3) synthetic cannabinoids, such 
as WIN-55, 212-2, JWH-133, and (R)-methanandamide (R-Met), which are developed 
in a laboratory and bear structural similarities to either natural or endogenous 
cannabinoids (Sarfaraz et al., 2008). 
The endogenous cannabinoid system consists of the cannabinoid receptors, their 
endogenous ligands (endocannabinoids) and the proteins responsible for their synthesis 
and inactivation (Bisogno et al., 2005). In mammals, the endocannabinoid system has 
effects on many organ systems and it regulates cardiovascular, nervous, digestive, 
metabolic, reproductive and immune functions (Mackie, 2006; Pacher et al., 2006). 
Studies to date indicate that the endocannabinoid system usually has suppressive 
effects, exemplified by decreased contractility in the heart, vasorelaxation, 
neuroprotection in acute and chronic neurological conditions and anti-inflammatory 
effects (Flygare and Sander,  2008). 
It was earlier thought that endocannabinoids exert their physiologic and behavioral 
effects via non-specific interaction with cell membranes. In the early 1990s, the two G 
protein-coupled receptors (GPCR); cannabinoid receptor type-1 (CB-1) (Matsuda et 
al., 1990; Gérard et al., 1991) and cannabinoid receptor type-2 (CB-2) (Munro et al., 
1993) were cloned. Based on their predominant expression in the central nervous 
system and in the peripheral immune system, CB-1 and CB-2 were initially denoted the 
central and the peripheral cannabinoid receptor, respectively. It later became evident 
that CB-1 is also found at peripheral nerve terminals and in non-neuronal tissues, e.g. 
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the pituitary gland, immune cells, vascular endothelium, eye, ileum and reproductive 
tissues (Pertwee, 2005; Bifulco et al., 2006), and that CB-2 is expressed also in the 
central nervous system (Van Sickle et al., 2005). However, the major role played by 
CB-1 is the inhibition of the release of neurotransmitters, whereas CB-2 mainly 
modulates functions of the immune system by regulating cell migration and cytokine 
release. The cannabinoid receptors participate in the regulation of cell survival 
(Guzmán et al., 2001). In this context, signaling via MAPK and PI3K-AKT as well as 
generation of ceramide have been implicated (Guzmán, 2003) 
Endocannabinoids have several characteristics that distinguish them from classical 
neurotransmitters. According to the traditional view, neurotransmitters are synthesized 
in presynaptic neurons and stored in vesicles to be released after neural activation and 
subsequent calcium influx (Burnstock, 2009). On the contrary, endocannabinoids are 
synthesized from membrane lipids in postsynaptic neurons after calcium influx that 
follows neural activation. AEA synthesis primarily depends on the activity of 
phospholipase D, whereas 2-AG synthesis involves phospholipase C. Also diverging 
from the classical concept of neurotransmission, endocannabinoids immediately diffuse 
to the synaptic cleft, instead of being stored in vesicles due to their lipophilic nature 
(Piomelli, 2003; Kano et al., 2009). Complementing this picture, CB-1 receptors are 
mainly located in presynaptic terminals. Activation of CB-1 receptors leads to a 
decrease in synaptic transmission via a complex set of intracellular signaling cascades. 
Thus, endocannabinoids act as retrograde messengers, which are synthesized and 
released on demand following depolarization of the postsynapse to reach 
presynaptically localized CB-1 receptors, where they restrain the release of 
neurotransmitters (Wilson and Nicoll, 2002) (Figure V). 
In addition to cannabinoid receptors, the vanilloid receptor type 1 (transient receptor 
potential vanilloid 1, TRPV1) is well established as a target for AEA, while other 
receptors, e.g. the peroxisome-proliferator-activated receptor-γ (PPAR-γ, a nuclear 
receptor) and the GPR55 (G protein-coupled receptor) orphan receptor have also been 
suggested (Pertwee, 2005; Jonsson et al., 2006). AEA can also act as a modulator of 
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other signaling pathways; allosteric sites for AEA are present on muscarinic and 
glutamate receptors (Flygare and Sander,  2008). 
 
Figure V. Schematic representation of endocannabenoid actions:  
Endocannabinids are sythesized in and released from the membrane of postsynaptic neurons on demand 
after calcium influx (1). They activate presynaptic CB-1 receptors and restrain neural activity (2). AEA 
and 2-AG are removed from the synaptic cleft by uptake into the post and presynapse respectively (3). 
Once inside neurons, AEA binds TRPV1 (with consequences opposite to those of CB-1 activation) and 
undergoes hydrolysis by FAAH, wherease 2-AG is hydrolysed by MGL (4). (Adopted from Saito et al., 
2010) 
Abbreviations: 2-AG, 2-arachidonoyl glycerol; AA, arachidonic acid; AEA, anadamide; CB-1, 
cannabinoid receptor type 1; EtNH2, ethanolamine; FAAH, fatty acid amide hydrolase; MGL, monoacyl 
glycerol lipase; T, transporter; TRPV1, transient receptor potential vanilloid type-1.  
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1.6.2 Endocannabinoid inactivation 
Following release from the cells, AEA and 2-AG can act on molecular targets in an 
autocrine or paracrine manner, and are subsequently inactivated by cellular re-uptake 
and hydrolysis. The exact uptake mechanisms responsible for these processes are still 
unknown. Two possibilities have been proposed in this context: First, 
endocannabinoids might cross the cell membrane along a concentration gradient in a 
passive process not governed by any enzyme or transport protein. Second, a protein 
transporter might exist, which favors the movement of endocannabinoids through the 
cell membrane (Glaser, 2005). The later view is supported by experiments showing that 
the uptake process is saturable, temperature-dependent, and can be inhibited by specific 
compounds (Piomelli, 2003). However, an endocannabinoid transporter could not be 
identified and cloned yet. Once inside cells, endocannabinoids are catabolized by 
different enzymes.  
 
AEA undergoes hydrolysis by the enzyme fatty acid amide hydrolase (FAAH) (Ahn et 
al., 2008; Ueda et al., 2010), an integral membrane protein identified primarily in 
postsynaptic sites in rodents and primates. FAAH breaks down AEA into arachidonic 
acid and ethanolamine. 2-AG, in contrast, is hydrolyzed mainly by presynaptically 
localized monoacylglycerol lipase (MGL) into arachidonic acid and glycerol (Dinh et 
al., 2002, Blankman et al., 2007) (Figure V). Interestingly, biological activity of the 
degradation products has been reported. Ethanolamine has been shown to protect 
neuroblastoma cells against apoptosis (Matas et al., 2007), and arachidonic acid can be 
further metabolized to leukotrienes and prostaglandins, the well-known inflammatory 
mediators.  
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1.6.3 Changes in the endocannabinoid system in cancer 
Little is currently known about the biological role of the endocannabinoid system in 
cancer physiopathology (Velasco et al., 2012). Although there are some exceptions that 
may be tumor type-specific, both cannabinoid receptors and their endogenous ligands 
are generally up-regulated in tumor tissue compared with non-tumor tissue (Guzmán, 
2003; Caffarel et al., 2006; Malfitano et al., 2011). Additionally, different studies have 
associated the expression levels of cannabinoid receptors, endocannabioids and 
endocannabinoid-metabolizing enzymes with tumor aggressiveness (Nomura et al., 
2010; Thors et al., 2010; Malfitano et al., 2011) which suggest that the 
endocannabinoid system may be over-activated in cancer and so it may be pro-
tumorigenic (Guzmán, 2003). In support of this, in mouse models of cancer, genetic 
ablation of CB-1 and CB-2 receptors reduces ultraviolet light-induced skin carcinogen-
esis (Zheng et al., 2008), and CB-2 receptor overexpression enhances predisposition to 
leukemia following leukemia virus infection (Joosten et al., 2002).  
Conversely, and in line with evidence that the pharmacological activation of 
cannabinoid receptors reduces tumor growth (Guzmán, 2003; Sarfaraz et al., 2008), 
the up-regulation of endocannabinoid-degrading enzymes has been observed in 
aggressive human tumors and cancer cell lines (Nomura et al., 2010; Thors et al., 
2010), indicating that endocannabinoid signaling can also have a tumor-suppressive 
role. In support of this, the deletion of CB-1 receptors accelerates intestinal tumor 
growth in a genetic mouse model of colon cancer (Wang et al., 2008); increased 
endocannabinoid levels diminish azoxymethane-induced precancerous lesions in the 
mouse colon (Izzo et al., 2008); and a reduction in the expression of the 
endocannabinoid-degrading enzyme monoacylglycerol lipase reduces tumor growth in 
xenografted mice (Nomura et al., 2010). 
Elevated levels of endocannabinoids (AEA and 2-AG) have been reported in several 
types of tumors when compared with their normal counterparts e.g. glioblastoma, 
meningioma, pituitary adenoma, prostate and colon carcinoma and endometrial 
sarcoma (Pagotto et al., 2001; Schmid et al., 2002; Ligresti et al., 2003; Nithipatikom 
et al., 2004; Petersen et al., 2005).  
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Both AEA and 2-AG have been shown to be increased in human colorectal 
adenomatous polyps and carcinomas compared to normal colorectal mucosa (Ligresti et 
al., 2003), suggesting that these endocannabinoids increase when passing from normal 
to transformed mucosa. Similarly, AEA levels were enhanced by 17-fold in 
glioblastomas whereas meningiomas were characterized by a massively enhanced level 
of 2-AG (Petersen et al., 2005). The overall interpretation of these data could be that 
endocannabinoids act as endogenous tumor suppressors. 
1.6.4 Cannabinoids in the treatment of cancer 
The therapeutic properties of marijuana have been known for millennia, but the use in 
the clinic of either plant-derived preparations or pure cannabinoids is still very limited 
due to their psychotropic side effects (Di Marzo, 2008). In the context of cancer, only 
two cannabinoid-based medicines can be prescribed, and for very specific indications to 
date. Sativex
®
 (nabiximols, an oromucosal spray containing plant extracts enriched in 
THC and cannabidiol at an approximate 1:1 ratio) has been recently approved in 
Canada for the treatment of cancer-associated pain (Brown et al., 2013). In addition, 
Marinol
®
 and Cesamet
®
 (oral capsules of nabilone – a synthetic THC analog) can be 
prescribed to prevent nausea and vomiting elicited by standard chemotherapeutic 
regimes (Brown et al., 2013). Aside from these palliative actions, recent preclinical 
evidence suggests that cancer patients might benefit from cannabinoids in an additional 
manner: since the late 1990s, an important amount of experimental data has shown that 
these compounds exert anti-tumor effects in different models of cancer, ranging from 
cell cultures to xenografted and genetically engineered mice (Hermanson and Marnett, 
2011). Interestingly, some – if not all – of these effects have been observed in tumor 
cells from very different origin, including gliomas, melanomas, carcinomas of the 
breast, skin, lungs, liver, pancreas, colon, prostate, and lymphomas amongst others, 
which indicates that cannabinoid anti-tumor action has a general rather than tumor-type 
specific nature (Velasco et al., 2012). 
 
The proposed mechanisms for such efficacy are complex and may involve cytotoxic or 
cytostatic effects, apoptosis induction, anti-metastatic effect accompanied by inhibition 
of neo-angiogenesis and tumor cell migration (Velasco et al., 2012). Moreover the 
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effect, depending on the type of cannabinoid and the target tissue, is CB-1, CB-2 or 
TRPV1 receptor-dependent or sometimes receptor independent (e.g. lipid rafts, 
cyclooxygenase, PPAR) (Pisanti and Bifulco, 2009) (Figure VI). A schematic 
representation of the major signaling pathways that are implicated in the activation of 
different cannabinoid receptor subtypes through their agonists and their involvement in 
these processes is summarized in Figure VII. 
 
 
Figure VI. Effects of cannabinoids in cancer (Adopted from Pisanti and Bifulco, 2009). 
Abbreviations: CB1, Cannabinoid receptor 1; CB2, Cannabinoid receptor 2; TRPV1; Transient receptor 
potential vanilloid 1  
Glioma 
Breast cancer 
Thyroid cancer 
Colon cancer 
 
Prostate cancer 
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Figure VII. Schematic representation of different mechanisms/signaling pathways through which 
cannabinoids impact apoptosis, proliferation, angiogenesis and migration: The figure depicts the 
main signaling cascades elicited downstream of CB receptor activation by endocannabinoids and 
cannabinoids, which affect all the hallmarks of cancer: inhibition of cell proliferation; cell-cycle arrest; 
induction of cell death (apoptosis and autophagy); prevention of tumor progression (cancer cell vascular 
adhesiveness, invasiveness, and metastasis formation); inhibition of angiogenesis in tumor environment; 
and inhibition of the epithelial–mesenchymal transition. (Adopted from Pisanti et al., 2013) 
Abbreviations: AC, adenylyl cyclase; AKT, protein kinase B; AR, androgen receptor; ATP, adenosine 
triphosphate; Bax, pro-apoptotic protein; Bcl2, antiapoptotic protein; brca1, breast cancer susceptibility 
gene product; cAMP, cyclic adenosine monophosphate; CB-1, cannabinoid receptor 1; CB-2, 
cannabinoid receptor 2; Cdc2, p34 cyclin-dependent kinase 1; CDK, cyclin-dependent kinases; EGF, 
epidermal growth factor; ERK, extracellular regulated kinase; GPR55, G protein-coupled receptor 55; 
H2O2, hydrogen peroxide; p27/KIP1, cyclin kinase inhibitor; PRL, prolactin receptor; p53, p53 protein; 
p21ras, p21 ras protein; PI3K, phosphatidyl inositol 3 kinase; PKA, protein kinase A; PKB, protein 
kinase B; PSA, prostate-specific antigen; Raf-1, protein Raf-1; Trk, high-affinity nerve growth factor 
receptor; TRPV1, transient receptor potential cation channel V1. 
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1.6.5 Side effects of direct cannabiniods agonists 
The applicability of direct cannabinoid agonists is limited in clinical practice due to 
their psychoactive effects (Di Marzo, 2008). Cannabinoid treatment may cause 
addiction and tolerance, induce sedative effects, and impair learning and memory. In 
general, low doses tend to induce anxiolytic activity, whereas higher doses may induce 
opposite effects (Moreira et al., 2009; Moreira and Wotjak, 2009). The reasons for 
these differences remain to be determined. They might be attributed to dose-dependent 
actions upon different brain regions and neural populations (Moreira and Wotjak, 
2009). Moreover, high cannabinoid concentrations may lead to desensitization/ 
internalization of CB-1 receptors, thus resulting in decreased endocannabinoid 
signaling. It is tempting to assume that such processes account for the paradoxical 
effects of cannabis consumption on emotional responses such as episodes of anxiety 
and panic (Saito et al., 2010). 
As the unwanted psychotropic effects of cannabinoids are mediated largely or entirely 
by CB-1 receptors in the brain (Guzmán, 2003); a first possibility would be to use 
cannabinoids that target CB-2 receptors. Selective CB-2 receptor activation in mice 
induces regression of gliomas (Sánchez et al., 2001) and skin carcinomas (Casanova et 
al., 2003) and can also inhibit pain (Malan et al., 2003) in the absence of obvious signs 
of psychoactivity but its use resulted in immunosuppressive effects typical of plant 
cannabinoids, which seem to be mediated mostly by the CB-2 receptors (Guzmán, 
2003). Another strategy would be to manipulate the effects of endocannabinoids. 
Achieving high endocannabinoid levels in the location of the tumors by selectively 
inhibiting endocannabinoid degradation has proved successful in animal models, as 
drugs that block anandamide breakdown exert antitumor effects with little 
psychoactivity (Bifulco et al., 2004). 
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1.6.6 Pharmacological manipulation of the endocannabinoid system 
 
1.6.6.1 Attenuation of endocannabinoid signaling  
Rimonabant (SR141716A) was the first CB-1 receptor antagonist synthesized (Rinaldi-
Carmona et al., 1994). This drug has provided invaluable insights into the physiology 
of the endocannabinoid system as well as in the pharmacology of cannabinoids. In the 
meantime, several other CB-1 antagonists have been developed, including AM-251 
(Gatley et al., 1996). As for the other cannabinoid receptors, selective CB-2 antagonists 
have also been developed, such as SR144528 (Pertwee, 2008). In addition, there are 
also antagonists for TRPV1 receptors, such as capsazepine (Di Marzo et al., 2008). By 
specific blockade of CB-1, CB-2 receptors and TRPV1 channels, it is possible to 
measure cellular, physiological or behavioral consequences of attenuated 
endocannabinoid signaling. 
 
1.6.6.2 Facilitation of endocannabinoid signaling  
Drugs that enhance the endocannabinoid action may provide a more subtle strategy for 
pharmacological interventions than direct activation of cannabinoid receptors. Given 
that endocannabinoids are produced and released on-demand, compounds interfering 
with endocannabinoid uptake and degradation could increase endocannabinoid 
signaling. Such drugs are expected to induce fewer side effects compared to direct 
agonists (Saito et al., 2010). 
 
Two main strategies have emerged for increasing endocannabinoid signaling at the 
level of their receptors: First, chemical compounds, such as N-arachidonoyl 
phenolamine (AM-404), VDM-11 or UCM-707, may interfere with the uptake process 
of the endocannabinoids, thereby increasing the availability of endocannabinoids at CB 
receptors (Beltramo et al., 1997; Giuffrida et al., 2001). However, their exact 
mechanisms of action still remain to be characterized. Moreover, these compounds lack 
specificity, as they may also interfere with endocannabinoid degradation and TRPV1 
channels (Piomelli, 2003). Second, a very promising strategy for enhancing 
endocannabinoids signaling is based on the inhibition of their hydrolysis. Specific 
inhibitors of FAAH and MGL have been developed, which are able to increase the 
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levels of AEA and 2-AG, respectively. The most prominent inhibitor of FAAH is URB-
597, which causes a 5-fold increase in the brain levels of AEA (Kathuria et al., 2003), 
thus corroborating findings obtained with genetic deletion of FAAH (Cravatt et al., 
2001). MGL, in turn, is inhibited, among others, by JZL184, which causes an 8-fold 
increase in 2-AG tissue content (Long et al., 2009). 
1.6.7 Targeting inactivation of endocannabinoids as an anticancer therapy 
The major difference between the action of endogenous and exogenous cannabinoids is 
the on-demand activation of the endocannabinoid system in a temporally and spatially 
restricted manner (Saito et al., 2010). 
 
The degradation of endocannabinoids is an active and rapid process. Therefore, 
blocking the degradation pathway may enhance the anti-proliferative effects of AEA 
and has beneficial effects in cancer treatment. Indeed, treatment of human breast cancer 
cells in-vitro with palmitoylethanolamide enhanced the anti-proliferative effects of 
AEA (Di Marzo et al., 2001). This agent was shown to reduce the expression of FAAH 
up to 30-40% thereby allowing the accumulation of AEA and increasing its anti-
proliferative effects (Di Marzo et al., 2001). In addition, intra-tumoral administration of 
VDM-11 or AA-5-HT to athymic mice xenografted with thyroid tumor increased the 
intra-tumoral levels of AEA and significantly decreased tumor volume (Bifulco et al., 
2004). The anti-proliferative actions of these agents could be only partly inhibited by 
the pretreatment with the CB-1 receptor antagonist, suggesting that endocannabinoids 
control tumor growth in-vivo by both CB-1 mediated and non CB-1 mediated 
mechanisms (Bifulco et al., 2004). Regardless of the molecular mechanism by which 
AEA and other endocannabinoids regulate tumor growth, inhibitors of their inactivation 
might be useful for the development of novel anticancer drugs (Bifulco et al., 2004). 
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1.6.8 OMDM-2 
OMDM-2 is an oleic acid derivative with a modified phenyl head group substitution 
(Figure VIII). This compound, unlike the widely used AM-404, is inactive as fatty 
acid amide hydrolase inhibitor and does not activate the vanilloid TRPV1 receptors (De 
Lago et al., 2004). Unlike both AM-404 and VDM-11, it is also metabolically stable, 
and is among the most potent inhibitors ever characterized of AEA cellular uptake by 
isolated intact cells (Ortar et al., 2003). Like other similar inhibitors, OMDM-2 is 
almost inactive as a direct agonist at cannabinoid CB-1 and CB-2 receptors. Therefore 
its efficacy cannot be explained by the direct activation of these receptors especially 
when used over the concentration range required for AEA uptake inhibition (3-10 µM) 
(Ortar et al., 2003).   
 
OMDM-2 does not show any significant activity on the motor behavior that would 
render it unique among the AEA uptake inhibitors developed so far (De Lago et al., 
2004; Nicolussi et al., 2014). Finally, this compound does not exhibit drug-reinforcing 
effects in normal rodents, and hence are not likely to induce dependence (Bortolato et 
al, 2006; Vlachou et al, 2006). Thus far, only one report has been explicitly dedicated 
to the anti-proliferative activity of OMDM-2 in cancer. The drug reduced the viability 
of C6 glioma cells over a concentration range similar to that required for the inhibition 
of AEA uptake in-vitro, albeit with a longer latency (De Lago et al., 2006). 
Hence, the current study aims at more in-depth evaluation of the in-vitro and in-vivo 
antitumor potential of OMDM-2, in addition to investigate the possible mechanisms 
involved in this activity. This would enhance the credibility of its usefulness in cancer 
therapy.  
 
Figure VIII. Structure of OMDM-2. 
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1.7 Curcumin 
Turmeric has been widely used for centuries in indigenous medicine for the treatment 
of a variety of inflammatory conditions and other diseases (Ammon and Wahl, 1991). 
Curcumin is the most active component of turmeric. It is a bis-α, β-unsaturated β 
diketone and exists in equilibrium with its enol tautomer (Figure IX). The bis-keto 
form predominates in acidic and neutral aqueous solutions and in the cell membrane 
whereas the enolate form is found above pH 8 (Sharma et al., 2005). It exhibits low 
oral bioavailability in rodents and may undergo intestinal metabolism; absorbed 
curcumin undergoes rapid first-pass metabolism and excretion in bile. Curcumin is 
relatively insoluble in water, but dissolves in acetone, dimethylsulphoxide and ethanol.  
 
 
 
 
Figure IX. Tautomerism of curcumin under physiological conditions. 
 
Curcumin has been shown to possess wide range of pharmacological activities. 
Curcumin exhibits strong antioxidant activity comparable to vitamins C and E 
(Mansouri et al., 2012). Curcumin with its proven anti-inflammatory properties has 
been shown to have several therapeutic advantages. It was shown to be a potent 
scavenger of a variety of reactive oxygen species including superoxide anion radicals, 
hydroxyl radicals (Reddy and Lokesh, 1994) and nitrogen dioxide radicals (Sreejayan 
and Rao, 1997). It was also shown to inhibit lipid peroxidation in different animal 
models (Reddy and Lokesh, 1992; Sreejayan and Rao, 1994).  
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In addition, Curcumin also possesses anti-viral, anti-fungal, and anti-bacterial activities 
(Maheshwari et al., 2006). 
 
Numerous studies have found that curcumin has a dose dependent chemopreventive 
effect in several animal tumor bioassay systems including colon, duodenal, stomach, 
esophageal and oral carcinogenesis. It has been shown to reduce tumors induced by 
benz(a) pyrene and 7, 12 dimethyl benz(a)anthracene, tumor promotion induced by 
phorbol esters  on mouse skin, on carcinogen-induced tumorigenesis in the fore 
stomach and N-ethyl-N′-nitro-Nnitrosoguanidine- induced duodenal tumors 
(Maheshwari et al., 2006). 
 
The molecular bases of the anti-carcinogenic and the chemopreventive effects of 
curcumin are attributed to its anti-proliferative, anti-angiogenic, and anti-metastatic 
activities (Maheshwari et al., 2006; Hasima and Aggarwal, 2012). These activities 
depend on the ability of curcumin to affect several targets including transcription factors 
(eg. NF-κB), growth regulators (eg. EGF), inflammatory biomarkers (eg. CXCR4), 
cellular components, angiogenesis regulators (eg. VEGF), oncoproteins, and protein 
kinases (Figure X). 
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Figure X. Cancer targets and curcumin (Adopted from Hasima and Aggarwal, 2012). 
(Abbreviations page i)   
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1.8 Aim of the work 
We evaluated the antitumor activity of a systemic administration of OMDM-2 in 
comparison to the direct cannabinoid agonist, R-methanandamide in Ehrlich ascites 
carcinoma (EAC) bearing mice using carboplatin as a reference standard. We further 
investigated underlying mechanism(s) of action of OMDM-2 as an anticancer agent, as 
well as an optimization strategy by combining OMDM-2 with either the natural product 
curcumin or benchmark chemotherapeutic agents. 
Our strategy depends on the manipulation of the effects of endogenous cannabinoids by 
using OMDM-2 which enhances the half-life of endogenous cannabinoids by 
preventing their reuptake and hence degradation. Depending on the “on demand” nature 
of endogenous cannabinoids, this strategy should lead to an indirect enhancement of the 
functionality of endocannabinoid receptors only in those tissues and cells in which 
there is an ongoing synthesis, release, action and degradation of endocannabinoids like 
in cancer cells. With respect to adverse events, the reuptake inhibitors should be more 
selective and safer than direct agonists.  
Objectives: 
I. In-vivo evaluation of the antitumor activity of the systemic administration of 
OMDM-2 in comparison with R-Methanandamide (R-Met) in Ehrlich Ascites 
Carcinoma (EAC) bearing mice using carboplatin as a reference standard. The 
following parameters were assessed: 
1. Tumor volume and relative tumor volume. 
2. Tumor weight (time course). 
3. Tumor growth time (TGT) and tumor growth delay time (TGDT). 
4. Percentage survival of animals. 
5. Mean survival time (MST). 
6. Percentage increased life span (%ILS). 
7. Hematological parameters. 
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II. In-vivo evaluation of the possible mechanisms of actions involved in this activity:  
1. Assessment of the involvement of CB-1 receptor by using the 
pharmacological inhibitor NIDA 41020. 
2. Assessment of the anti-angiogenic activity using Evans blue method and 
investigation of the involvement of CB-1 receptor in this activity. 
3. Evaluation of the time course of serum levels of TGF-β1 in EAC bearing 
mice and in the treatment groups. 
4. Evaluation of the time course expression of the CD-105 receptor in tumor 
tissue in EAC bearing mice and in the treating groups. 
 
III. In-vitro investigation of the cytotoxic activity of OMDM-2 against 2 different 
human cell lines MCF-7 (breast cancer cells) and U-87 (glioma cells) using 
Resazurin based assay.  
 
IV. Investigation of mechanisms involved in the cytotoxic activity of OMDM-2:  
 1. Assessment of the involvement of the CB-1 and TRPV1 receptors by 
using their pharmacological inhibitors NIDA 41020 and Capsazepine, 
respectively. 
2. Assessment of the type of cell death by evaluation of single-stranded 
DNA fragments at different time points (ELISA), DNA laddering 
(Electrophoresis), and the morphology of the cells. 
3. Assessment of the involvement of Caspase-3 by measuring its activity 
spectrophotometrically at different time points. 
4. Investigation of the signal transduction pathway leading to OMDM-2 
induced anti-proliferative activity using Western blot analysis. 
V. Investigation of the possible optimization of OMDM-2 treatment by 
combination with curcumin or benchmark chemotherapeutic agents. 
Materials and Methods 
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2. Materials  
2.1 Animals 
2.1.1 Ethics statement 
All animal experiments were performed within strict adherence to the criteria outlined in 
the NIH "Guide for Care and Use of Laboratory Animals" (publication #86-23 revised 
1985) (Louhimies, 2002) and the protocol was approved by the Ethical and Animal Care 
Committee at Sinai University. All efforts were made to ameliorate animal suffering. 
Animal sacrifice was performed by cervical dislocation. 
 
2.1.2 Mice 
Male and female Swiss albino mice (age 5-6 weeks)  (weight 20-25 g) were obtained from 
the Modern Veterinary Office for laboratory animals, Cairo, Egypt and housed under 
controlled conditions (25±1 °C constant temperature, 55% relative humidity, and 12 hrs 
dark / light cycles). All animals were allowed to acclimatize under standard animal house 
conditions (Faculty of Pharmacy, Sinai University) for 1 week before assignment to the 
experimental protocol. Food and water were allowed ad libitum during the study period.  
 
2.2 Tumor cell lines 
A- Ehrlich ascites carcinoma 
Ehrlich ascites carcinoma (EAC) cell line, used for in-vivo studies, was purchased from 
Tumor Biology Department, National Cancer Institute, Cairo University. EAC is a murine 
spontaneous breast cancer that served as the original tumor from which an ascites variant 
was obtained. On intraperitoneal (i.p.) inoculation, an ascites rich in tumor cells was 
produced. The tumor cell line was maintained in our laboratory by serial i.p. passage into 
Swiss female albino mice at a 7-10 days interval. 
B- Human breast cancer cell line (MCF-7 cells)  
Human breast cancer (estrogen receptor positive) MCF-7 cell line, used for in-vitro studies, 
was purchased from the German collection of microorganisms and cell cultures (DSMZ, 
ACC 115), Germany. The source of MCF-7 cells is the mammary gland, and the disease 
related to these cells is adenocarcinoma of the breast. The morphology of MCF-7 cells is 
epithelial and they are adherent in nature. The MCF-7 cell line retains several 
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characteristics of differentiated mammary epithelium including the ability to process 
estradiol via cytoplasmic estrogen receptors and the capability of forming domes.  
C- Human primary glioblastoma cell line (U-87 MG cells)  
Human glioblastoma grade IV cell line, used for in-vitro studies, was purchased from the 
cell line service (CLS). U-87 is a highly malignant anaplastic glioma clone derived from a 
44-year-old Caucasian woman. The morphology of U-87 MG cells is epithelial and they 
are adherent in nature.  
2.3 Drugs 
 (R)-(+)-Methanandamide (in TocrisolveTM 100):  
The non-selective direct cannabinoid agonist, R-Methanandamide (R-Met) was 
purchased from Tocris bioscience, Germany. This product was supplied as an 
emulsion at a concentration of 10 mg/ml in a soya oil/water (1:4) using the block co-
polymer, Pluronic F68 as an emulsifier. R-Met was administered at a dose of 0.5 
mg/kg, i.p. every third day, after dilution with distilled water (Bifulco et al., 2004).  
 
 OMDM-2: 
The endocannabinoid reuptake inhibitor, (S)-N-oleoyl-(1'-hydroxybenzyl)-2'-
ethanolamine (OMDM-2) was purchased from Cayman Chemical, Germany. It was 
supplied as a crystalline powder (Purity > 98%). In the current study, OMDM-2 was 
administered in-vivo at a dose of 5 mg/kg, i.p., every third day, after dissolving in 
DMSO (De Lago et al., 2004; Nicolussi et al., 2014). For in-vitro studies, the 
following concentrations were used for MCF-7 cells: 2.5 µM, 5 µM, 10 µM, 20 µM, 
40 µM and 80 µM. For U-87 cells, the following concentrations were used: 0.625 
µM, 1.25 µM, 2.5 µM, 5 µM, and 10 µM, 20 µM, 40 µM and 80 µM.  
 NIDA 41020:  
The CB-1 blocker, NIDA 41020 was purchased from Tocris bioscience, Germany. It 
was supplied as a white solid powder (Purity > 99%). NIDA 41020 is structurally 
similar to the widely used CB-1 blocker; rimonabant. In the current study, NIDA 
41020 was administered in-vivo (Bifulco M et al., 2004) at a dose of 0.7 mg/kg, i.p., 
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every third day, after dissolving in DMSO. For in-vitro studies, the following 
concentration was used, 0.2 µM. 
  Capsazepine: 
The TPRV1 blocker, capsazepine was purchased from Sigma Aldrich, Germany. It 
was supplied as an off-white solid powder (Purity > 98%). Capsazepine is a synthetic 
analogue of capsaicin. In the current study, capsazepine was used for in-vitro 
experiments after dissolving in DMSO at a concentration 1 µM.  
 
 Carboplatin: 
It was purchased from MP Biomedicals, LLC, France. It was supplied as off-white 
crystalline powder. Carboplatin was administered at a dose of 5 mg/kg, i.p., every 
third day, after dissolving in distilled water (Chen et al, 2007).  
  Paclitaxel:  
Semi-synthetic paclitaxel was purchased from Sigma Aldrich, Germany. Its growth 
inhibitor effect alone or in combination with OMDM-2 was examined in MCF-7 in-
vitro using the following concentrations: 10 nM, 100 nM, 1 µM, and 10 µM, 100 
µM. 
  Temozolomide:  
It was purchased from Sigma Aldrich, Germany. Its growth inhibitor effect alone or 
in combination with OMDM-2 was examined in U-87 glioma cells in-vitro using 
the following concentrations: 50 µM, 100 µM, 200 µM, 300 µM, and 400 µM.  
 Curcumin:  
It was purchased from Sigma Aldrich, Germany. It was supplied as yellow powder. 
Its growth inhibitory effect alone or in combination with OMDM-2 was examined 
against both MCF-7 and U-87 glioma cells in-vitro using the following 
concentrations: 5 µM, 10 µM, 20 µM, 30 µM, 40 µM, and 80 µM. 
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2.4 Chemicals and reagents 
2.4.1 Chemicals 
The sources of the chemicals used in this study are included in the following table: 
Table (I): List of chemicals 
Chemicals Source 
Acrylamide/bis-Acrylamide solution (30%) Sigma Aldrich, Germany 
Ammonium persulphate Sigma Aldrich, Germany 
Agarose  Sigma Aldrich, Germany 
Acetic acid Sigma Aldrich, Germany 
Bovine serum albumin (BSA) Pierce
TM
, Germany 
Dimethyl sulfoxide (DMSO)  Sigma Aldrich, Germany 
Ethylenediaminetetraacetic acid sodium salt (EDTA) Sigma Aldrich, Germany 
Evans blue Sigma, USA 
Ethidium bromide Sigma Aldrich, Germany 
Formaldehyde (37%) Al-Gomhorya Co., Egypt. 
Glycerol Merck, Germany 
Glycine Sigma Aldrich, Germany 
Methanol (100%) Applichem GmbH, Germany 
β-Mercaptoethanol Sigma Aldrich, Germany 
Protease inhibitor cocktail Sigma Aldrich, Germany 
Proteinase K Sigma Aldrich, Germany 
RNase Gentra Purgene, USA 
Sodium orthovandate Sigma Aldrich, Germany 
Sodium dodecyl sulfate solution (SDS, 20%) Biorad, Germany 
Sodium desoxycholate Sigma Aldrich, Germany 
Sodium chloride Sigma Aldrich, Germany 
Sodium fluoride (NaF) Sigma Aldrich, Germany 
Sodium pyrophosphate Sigma Aldrich, Germany 
N,N,N´,N´-Tetramethylethylenediamine (TEMED) Sigma Aldrich, Germany 
Tris Base (Trizma) Sigma Aldrich, Germany 
Tris HCl Sigma Aldrich, Germany 
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Chemicals Source 
Tween 20 Sigma Aldrich, Germany 
Triton X-100 Sigma Aldrich, Germany 
Trypan blue 
Al-Gomhorya Co., Egypt. & 
Sigma Aldrich, Germany 
  
2.4.2 Growth mediums 
 Roswell Park Memorial Institute – 1640 medium (RPMI-1640):  
It was purchased from Life technologies (Gibco), Germany and used for the growth 
of MCF-7 cells. It was supplemented with 10% fetal bovine serum gold (FBS), 
PAA, Germany; 0.1 mM non-essential amino acids, Life technologies (Gibco), 
Germany; 1 mM sodium pyruvate, Sigma Aldrich, Germany; 10 µg/ml human 
insulin solution, Sigma Aldrich, Germany, and 1% penicillin/streptomycin (10000 
IU/ml each)/fungizone (25 µg/ml), Promocell, Germany. 
 
 Minimum essential medium supplemented with L-glutamine (MEM): 
It was purchased from Life technologies (Gibco), Germany and used for the growth 
of U-87 MG cells. It was supplemented with 10% FBS, 0.1 mM non-essential 
amino acids, 1 mM sodium pyruvate, and 1% penicillin/streptomycin (10000IU/ml 
each)/fungizone (25 µg/ml). 
 
 Freezing media: 
Two different freezing media were prepared for the storage of each cell line. They 
were prepared as following: 70% medium + 20% FBS + 10% DMSO 
 
2.4.3 Solutions 
 Calcium and magnesium free-Dulbecco’s phosphate buffered saline (DPBS): 
It was purchased from Life technologies (Gibco), Germany. 
 
 Trypsin EDTA (10x): 
It was purchased from PAA, Germany. 5 ml stock solution were diluted with 45 ml 
DPBS.  
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 Western blot solutions 
 
RIPA lysis buffer for protein isolations: 
Tris HCl     20 mM 
Triton X-100     1% 
Glycerol    20 mM 
EDTA      2.5 mM 
Sodium pyrophosphate   10 mM 
NaF      50 mM 
SDS      0.1% 
Sodium desoxycholate   1% 
Protease inhibitor cocktail  1% 
Sodium orthovandate   0.5% 
 
10% Separation gel buffer (8 ml): 
Distilled water    3.2 ml 
Acrylamide/Bis-Acrylamide (30%) 2.67 ml 
1.5M Tris, pH 8.8    2 ml 
SDS (10%)     80 µL 
Ammonium persulphate (10%)  80 µL 
TEMED     8 µL 
 
6% Stacking gel buffer (5 ml): 
Distilled water    2.6 ml 
Acrylamide/Bis-Acrylamide (30%) 1 ml 
0.5M Tris, pH 6.8    1.25 ml 
SDS (10%)     50 µL 
Ammonium persulphate (10%)  50 µL 
TEMED     5 µL 
 
Freshly added immediately before lysis 
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Protein Sample buffer: 
Tris HCl, pH 6.8    50 mM 
SDS      2% (w/v) 
Glycerol     10% (v/v) 
Bromophenol blue    0.0025% (w/v) 
1 M DTT     10% (v/v) 
 
Laemmeli gel electrophoresis buffer (Running buffer): 
Tris Base    25 mM 
SDS      0.5% (w/v) 
Glycine     192 mM 
 
Towbin transfer buffer: 
Tris HCl     25 mM 
Glycine     192 mM 
Methanol     20% (v/v) 
 
TBS: 
Tris Base     20 mM 
NaCl      140 mM 
 
Wash buffer (TBST): 
Tris Base     20 mM 
NaCl      140 mM 
Tween 20     0.1% (v/v) 
 
Blocking solution: 
TBS      150 ml 
BSA     1% 
Tween 20     1% (v/v) 
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Antibody-Dilution-Buffer: 
TBS      20 ml 
BSA     1% 
Tween 20     0.1% (v/v) 
 
Harsh stripping buffer (100 ml): 
Buffer and strip membranes were prepared under a fume-hood 
Tris HCl (pH 6.8)    12.5 ml 
SDS (10%)    20 ml 
Distilled water    67.5 ml 
780 µl of β-Mercaptoethanol was added under fume-hood immediately before 
stripping. 
 
Western blotting luminol reagent (ECL, 32106): 
It was purchased from Thermo scientific, Germany. It was used for the detection of 
horseradish peroxidase (HRP) on immunoblots using the chemiluminescence 
imaging machine (PEQLAB, Germany). 
 
 DNA gel electrophoresis 
DNA lysis buffer (pH 8) 
Tris base    100 mM 
EDTA    0.5 mM 
NaCl     0.2 M 
SDS    0.5% 
 
TEA gel electrophoresis buffer 
Tris base    40 mM 
Acetic acid    20 mM 
EDTA     1 mM 
 
5x Sample buffer 
Glycerol    50% (v/v) 
EDTA     0.002 mM 
Bromo phenol blue   0.0025% (w/v) 
Xylene cyanol    0.0025% (w/v) 
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Agarose gel  
TAE     50 ml 
Agarose    1.5% (w/v) 
Ethidium bromide   10 µl 
 
Tris-EDTA buffer (TE buffer, pH 8) 
Tris HCl    10 mM 
EDTA    1 mM  
 
 EDTA solution: 
EDTA was used as an anticoagulant during blood collection (at a concentration of 29 
µg/ml). EDTA was also used for the preparation of citrate-EDTA buffer used in the 
immunohistochemistry. 
 Formaldehyde: 
It was used for the preparation of neutral buffered formalin (3.7%) by dissolving 4 
gm monobasic sodium phosphate and 6.5 gm dibasic sodium phosphate in 900 ml 
distilled water, to them 100 ml of formaldehyde (37%) was added and mixed well. 
This solution was used as a fixative for animal tissues for further histopathological 
examinations. 
 
 Trypan blue: 
0.1 gm of trypan blue powder was dissolved in 100 ml saline and was used for the 
staining of dead cells during the assessment of the number of viable cells (Lazarus et 
al., 1966). 
 Evans blue: 
1 gm of Evans blue powder was dissolved in 100 ml saline and was used for the 
angiostatic study (Lee et al., 1990). 
 Bradford solution (6916): 
It was purchased from Sigma Aldrich, Germany. It was used for spectrophotometric 
measurement of high protein concentrations ranging from 100 µg/ml to1400 µg/ml.  
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 Micro BCA reagent (23231): 
It was purchased from Thermo scientific, Germany. It was used for 
spectrophotometric measurement of low protein concentrations ranging from 2 µg/ml 
to 40 µg/ml. 
 
2.5 Kits 
 VEGF immunoassay kit [Quantikine, ELISA]: 
It was purchased from R&D systems
®
 (Clinilab, Egypt). It was used for the 
quantitative determination of VEGF concentrations in cell culture supernates. 
 
 Mouse TGF-β1 immunoassay kit [Quantikine, ELISA]: 
It was purchased from R&D systems
®
 (Clinilab, Egypt). It was used for the 
quantitative determination of mouse TGF-β1 concentrations in mouse serum. 
 
 In-vitro toxicology assay kit, resazurin based (TOX-8): 
It was purchased from Sigma Aldrich, Germany. It was used for fluorometrically 
determining the cell number as a function of the metabolic activity using the dye 
resazurin.  
 
 Cell death detection kit [ELISA]: 
It was purchased from Roche, Germany. It was used for the quantification of 
apoptosis by determination of mono-oligonucleosomes in the cytoplasmic fraction of 
cell lysate.  
 
 Caspase-3 colorimetric assay kit: 
It was purchased from R&D systems
®
, Germany. It was used for the determination 
of the enzymatic activity of the caspase-3 class of proteases in apoptotic cells by 
colorimetric reaction. 
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2.6 Antibody 
The following antibodies were used for Western blot. The source and the used dilutions 
are indicated in the following table: 
Table (II): List of antibodies 
Antibody Description Source 
 Primary Antibody  
ERK1/2 (H-72): sc-
292838 
Detects total p44/42 MAP-Kinase Santa 
Cruz Biotechnology, WB 1:500 dilution 
Rabbit 
 
Phospho-ERK1/2 
(Thr202/Tyr204) 
Detects phospho-p44/42 MAP-Kinase 
forms, Santa Cruz Biotechnology, WB 
1:1000 dilution  
Rabbit 
 
AKT 
Detects total Akt, Santa Cruz 
Biotechnology, WB 1:1000 dilution  
Rabbit 
 
Phospho-AKT 
Detects phospho-Akt, Santa Cruz 
Biotechnology, WB 1:1000 dilution  
Rabbit 
 
 Secondary Antibody  
Goat anti-rabbit IgG-
HRP 
Raised in goat against whole rabbit IgG 
conjugated to horse radish peroxidase, 
Santa Cruz Biotechnology, WB 1:2000 
dilution 
Goat 
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3. Methods 
3.1 Evaluation of in-vivo anti-tumor activity using EAC cells 
This experiment was carried out to determine the effect of R-Met or OMDM-2, either 
alone or in combination with CB-1 blocker pretreatment, on the tumor development and 
survival of animals using EAC cells implanted as a solid tumor in the right flank of male 
Swiss albino mice.  
Induction of Ehrlich solid tumor 
A- EAC cells preparation 
1- Ascitic fluid was withdrawn under aseptic conditions from tumor-bearing mice by 
needle aspiration from peritoneal cavity, 7-10 days after i.p. inoculation of EAC cells. 
2- EAC cells were tested for viability and contamination using trypan blue dye 
exclusion technique (Lazarus et al., 1966) in which equal volumes of trypan blue dye 
(0.1%) and the samples were mixed together. 10 µl of this mixture was mounted on a 
slide and cells were examined microscopically. Trypan blue dye stains dead cells only. 
Only EAC cells with at least 90% viability were used. 
3- Then, EAC cells were suspended in normal saline so that each 100 µl contains 
2.5x10
6
 EAC cells. Cells were counted under the microscope using Neubauer 
hemocytometer.    
B- Induction of solid tumor 
Each mouse was inoculated s.c in the right flank (after shaving this area) with 100 μl EAC 
suspension (2.5×10
6
 cells). 
 
3.1.1 Measurement of tumor volume (T.V) 
Tumor volume was measured using digital vernier caliber (Mitutoyo, Japan), starting seven 
days after tumor cells inoculation (when the tumor becomes palpable), every third day 
throughout the experiment. Relative tumor volume (RTV) and tumor growth time (TGT) 
were calculated. 
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 The tumor volume was calculated after seven days using the following 
formula: 
Tumor Volume (mm
3
) = 0.5X
2
 Y 
Where X, and Y are the minor and major axes, respectively (Attia and Weiss, 
1966). 
 Relative tumor volume was calculated by dividing the mean tumor volumes of 
the treated groups by the mean tumor volumes of the control group (Chen et al., 
2008). 
 
 Tumor growth time (TGT) was calculated as the average days required by the 
tumor to reach double, triple, or quadruple the initial tumor volume (Attia and 
Weiss, 1966). 
  
3.1.2 Determination of mean survival time (MST) and increase in the life span (%) 
Animals were monitored and mortality was recorded daily along the study period (89 days, 
when last animal died) to calculate percentage survival of animals, mean survival time 
(MST), and percentage increased life span among all animals. 
 Percentage survival of animals: mice were followed daily and percentage 
survival was calculated in each group as: 
(Number of living animals / initial total number of animals) × 100  
  Mean survival time (MST): (sum of survival days of all mice in each group) / 
(total number of mice). 
 Percentage increased life span (%ILS) was calculated using the following 
formula: 
%ILS= [(mean survival time of treated group / mean survival time of control 
group)-1] × 100 
An enhancement of life span by 25% or more was considered as effective antitumor 
response (Mazumdar et al., 1997). 
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3.2 Angiostatic activity (vascular permeability) 
The objective of this study was to assess the angiostatic activities of treatments on EAC-
bearing male Swiss albino mice according to the method of lee et al (1990). 
Each mouse was inoculated intradermally (i.d.) at 2 sites bilaterally on the lower 
ventral side (after shaving this area) with 100 μl EAC suspension (2.5x106 cells) on 
each site. 
 
The treatments were initiated 24 hours after tumor inoculation and given for a single 
dose. The degree of angiogenesis was assessed by measuring the tumor vascular 
volume on day 3 as described: 
1. On day 3, each mouse was injected intravenously (iv) with 0.25 ml (1% w/v) Evans 
blue through the tail vein.  
2. Two minutes after dye injection, each mouse was sacrificed by cervical dislocation 
and the implantation sites were punched out.  
3. Each two skin discs were pooled up in 2 ml standard solution (mentioned below) 
and kept at room temperature for 24 hrs with occasional shaking.  
4. Following centrifugation, at 4000 rpm for 5 minutes, the absorbance of the 
supernatant was measured at 620 nm using spectrophotometer (Metertech, Model: 
Σ960, METERTECHNIC). 
 
Preparation of the standard solution: 
1. Two normal mice were injected iv, through the tail vein; with 0.25 ml of 1% 
(w/v) Evans blue. 
2. Two minutes thereafter, the blood was withdrawn from orbital sinus under 
light ether anesthesia using heparinized microcapillaries and layered on a 
solution of sodium sulfate (0.5%)/acetone (2/3 v/v) at a concentration of 2 
μl blood/ml. 
3. The suspension was kept at 4˚C for 24 hours.  
4. The supernatant (the standard solution) was then separated by centrifugation 
at 4000 rpm for 5 minutes and stored at 4˚C until use. 
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The results were expressed as percentage of angiogenesis which was calculated according 
to the following formula: 
 
  % Ang. = [(A-B)/(C-B)] × 100 
 
Where A, B and C represent the optical density measured at 620 nm derived from the 
treated tumor tissue, background, and control tumor tissue, respectively. 
3.3 Assay of serum TGF-β1 concentration using ELISA 
3.3.1 Principle 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for mouse TGF-β1 has been pre-coated onto a microplate. 
Standards, control or samples were pipetted into the wells and any TGF-β1 present was 
bound by the immobilized antibody. After washing away any unbound substances, an 
enzyme-linked polyclonal antibody specific for mouse TGF-β1 was added to the wells to 
sandwich TGF-β1 immobilized during the first incubation. Following a wash to remove any 
unbound antibody-enzyme reagent, a substrate solution is added to the wells and color 
develops in proportion to the amount of TGF-β1 bound in the initial step. The color 
development is stopped and the intensity of the color is measured, the sample values are 
then read off the standard curve. 
3.3.2 Preparation of samples 
The blood was withdrawn from the orbital sinus under light ether anesthesia. After clotting 
for 2 hours at room temperature, samples were centrifuged at 2000 X g (Universal 32R, 
Germany) for 20 min as recommended by the manufacturer. The separated sera were used 
for estimation of TGF-β1. Serum samples required 60-fold dilution into Calibrator Diluent 
RD5-53. 
 
3.3.3 Reagents 
 Mouse TGF-β1 Microplate: 96 well polystyrene microplate (12 strips of 8 wells) 
coated with a monoclonal antibody specific for mouse TGF-β1.  
 Mouse TGF-β1 Conjugate: 12.5 ml/vial of a polyclonal antibody against mouse 
TGF-β1 conjugated to horseradish peroxidase with preservatives.  
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 Mouse TGF-β1 Standard: 4 ng/vial of recombinant mouse TGF-β1 in a buffered 
protein base with preservatives; lyophilized.  
 Mouse TGF-β1 Control: Recombinant mouse TGF-β1 in a buffered protein base 
with preservatives; lyophilized.  
 Assay Diluent RD1-73: 12.5 ml/vial of a buffered solution with preservatives.  
 Calibrator Diluent RD5-53: 21 ml/vial of a 4-fold concentrated buffered protein 
solution with preservatives.  
 Wash Buffer Concentrate: 50 ml/vial of a 25-fold concentrated solution of buffered 
surfactant with preservatives.  
 Color Reagent A: 12.5 ml/vial of stabilized hydrogen peroxide.  
 Color Reagent B: 12.5 ml/vial of stabilized chromogen (tetramethylbenzidine).  
 Stop Solution: 23 ml/vial of a diluted hydrochloric acid solution.  
 Plate Covers: Adhesive strips.  
 
Additional reagents required for sample activation 
 Hydrochloric acid. 
 Sodium hydroxide. 
 HEPES, free acid (M.W. 238.3) 
 
Sample Activation 
10 μl of HCl (1 N) were added to 40 μl of serum, and mixed well. The sample was 
incubated for 10 minutes at room temperature, and then neutralized by adding 8 μl of 
NaOH (1.2 N)/0.5M HEPES, mix well. Prior to the assay, the activated sample was diluted 
with Calibrator Diluent 60-fold dilution. 
3.3.4 Assay procedure 
All reagents and samples were brought to room temperature before use.  
1. All reagents, standard dilutions, and activated samples were prepared.  
 
2. 50 μl of assay diluent RD1-73 were added to each well. 
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3. 50 μl of standard, control, or activated sample were added per well. The plate was 
gently tapped for one minute, and then covered with the adhesive strip provided and 
incubated for 2 hours at room temperature.  
 
4. Each well was aspirated and washed three times with the washing buffer. After the 
last wash, any remaining wash buffer was removed by aspirating or decanting. The 
plate was inverted and blotted against clean paper towels. 
 
5. 100 μl of mouse TGF-Β1 conjugate were added to each well, covered with a new 
adhesive strip, and incubated for 2 hours at room temperature. 
 
6. The aspiration/wash was repeated as in step 4. 
 
7. 100 μl of substrate solution were added to each well, and incubated for 30 minutes at 
room temperature and protected from light. 
 
8. 100 μl of stop solution were added to each well. The plate was gently tapped to 
ensure thorough mixing. 
 
The optical density of each well was determined within 30 minutes, using a microplate 
reader (Metertech, Model: Σ960, METERTECHNIC.) set to 450 nm. Correction 
wavelength was set to 570 nm.  
 
3.3.5 Calculation of results 
A standard curve was constructed by plotting the mean absorbance for each standard on the 
Y-axis against the concentration on the X- axis and the best fit curve was drawn through 
the points on the graph. Because serum samples have been diluted prior to the assay, their 
measured concentrations were multiplied by 60. 
Intra-assay Precision 
Our data: Standard deviation: 2.6-8.2, coefficient of variation (%): 4.5-6.5. 
Manufacturer: Standard deviation: 2.3-17.3, coefficient of variation (%): 1.9-2.9. 
Recovery (%)  
Manufacturer: 105-112. 
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3.4 Immunohistochemical analysis for intra-tumoral CD-105 
For immunohistochemical evaluation of CD-105, each mouse was inoculated i.d. at 2 
sites bilaterally on the lower ventral side (after shaving this area) with 100 μl EAC 
suspension (2.5x10
6
 cells) on each site.  
 
3.4.1 Preparation of tissue specimens 
After cervical dislocation, tumor discs were taken out and fixed in 3.7% neutral buffered 
formalin up to 24 hrs for assessment of intra-tumoral expression of CD-105 receptor. After 
fixation, processing was completed using an automatic tissue processor. Tissues were 
dehydrated using graded alcohols, cleared with xylene, and infiltrated with paraffin wax. 
The tissues were subsequently embedded with paraffin wax in molds. Tissue blocks were 
stored at 4-25ºC on completion of embedding. Sectioned tissues were collected on clean 
glass slides. 
CD-105 evaluation was performed using 4 µm paraffin-embedded sections applying 
streptavidin-biotin-peroxidase method. Endogenous peroxidase activity was quenched by 
incubating the specimen for 10 minutes with 3% hydrogen peroxide. The specimens were 
then incubated with mouse monoclonal anti-CD-105 in the humidity chamber at 4ºC 
overnight. After conjugation with streptavidin-biotin-peroxidase complex, coloring was 
performed with 3,3´-diaminobenzidine (DAB) substrate-Chromogen and Mayer 
Hematoxylin was used for counter staining.  
 
3.4.2 Reagents 
 Peroxidase block: 3% hydrogen peroxide in water. 
 Biotinylated link: Biotin labeled affinity isolated goat anti-rabbit and goat anti-
mouse immunoglobulins in phosphate buffered saline (PBS), containing 
stabilizing protein and 0.015 M sodium azide. 
 Streptavidin-HRP: Streptavidin conjugated to horseradish peroxidase in PBS 
containing stabilizing protein and anti-microbial agents. 
 DAB substrate buffer: Imidazole-HCL buffer pH 7.5 containing hydrogen 
peroxide and an anti-microbial agent. 
 DAB chromogen: 3,3´-diaminobenzidine in chromogen solution. 
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3.4.3 Antigen retrieval 
Antigen retrieval was performed by using Triology (Cell Marque, CA-USA. Catalog no. 
920p-06) which is a product that combines the three pretreatment steps: de-paraffinization, 
rehydration and antigen unmasking. Using this product enhances standardization of the 
pretreatment procedure, thereby producing more consistent and more reliable results. 
Slides were placed in a Koplin’s jar filled with 200 ml of triology working solution and the 
jar was securely positioned in the autoclave. The temperature of autoclave was adjusted to 
120
oC and maintained for 15 min after which pressure was released and the Koplin’s jar 
was removed to allow slides to cool for 30 min. Sections were then rinsed in PBS and were 
stained according to the staining protocol mentioned in the following section.  
3.4.4 Staining Protocol 
STEP 1 PEROXIDASE BLOCK 
 Excess liquid was tapped off using gauze pad, carefully wiped around the specimen 
to remove any remaining liquid and to keep reagents within the prescribed area. 
 Enough hydrogen peroxide was applied to cover specimen. 
 Incubated for 10 minutes. 
 Rinsed gently with buffer solution from a wash bottle and placed in fresh buffer 
bath. 
 
STEP 2 BACKGROUND STAINING BLOCK 
 Broad spectrum LAB-SA detection kit from Invitrogen (Catalog no. 85-9043) was 
used to visualize any antigen-antibody reaction in the tissues. 
 Background staining was blocked by putting on each slide 3 drops of 10% goat non 
immune serum blocker supplied with the aforementioned kit. 
 Incubated in a humidity chamber for 10 min.  
 Without washing, excess serum was drained from each slide  
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STEP 3 PRIMARY ANTIBODY 
 Enough of the ready to use mouse monoclonal anti-endoglin antibody (Thermo 
scientific, USA, Catalog no. MS-1290-PCS) was applied to cover specimen. 
 Incubated overnight at 4ºC. 
 Slides were rinsed gently with buffer solution from a wash bottle and placed in 
fresh buffer bath. 
 
 STEP 4 BIOTINYLATED LINK 
 Excess liquid was immediately tapped off and slides were wiped as mentioned 
before. 
 Enough drops from link antibody were applied to cover specimen. 
 Incubated for 20 minutes. 
 Slides were rinsed as mentioned in step 2. 
 
STEP 5 STREPTAVIDIN-HRP 
 Slides were wiped as mentioned before. 
 Enough drops of the streptavidin reagent were applied to cover specimen. 
 Incubated for 20 minutes. 
 Slides were rinsed as mentioned before. 
 
STEP 6 SUBSTRATE-CHROMOGEN SOLUTION 
 DAB substrate-chromogen solutions were removed from refrigerated (2-8oC) 
storage. 
 DAB was prepared by adding 20 µL of the DAB chromogen per 1 ml of substrate 
buffer. 
 Slides were wiped as mentioned before. 
 Enough of the DAB substrate-chromogen solution was applied to cover specimen.  
 Slides were incubated for 5 minutes.  
 Rinsed gently with distilled water from a wash bottle. DAB substrate-chromogen 
waste was collected in a hazardous materials container for proper disposal. 
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STEP 7 MAYER'S HEMATOXYLIN COUNTERSTAIN 
 Slides were immersed in a bath of Mayer's hematoxylin. 
 Incubated for 2-5 minutes, depending on the strength of hematoxylin used. 
 Slides were rinsed in a bath of distilled or deionized water for 2-5 minutes.  
 
STEP 8 MOUNTING 
 Specimens were mounted and cover slipped with DPX mounting medium. 
 
3.4.5 Evaluation of endoglin receptor (CD-105) expression 
The expression of tissue CD-105 was determined by the presence of brown stained cells in 
the EAC tissue according to Bock et al (2011). For the evaluation of the CD-105 
expression, positive controls which had been prepared from invasive ductal breast 
carcinoma (Bancher-Todesca et al., 1997) were used. Those specimens were kindly 
donated by the Tumor Biology Department, National Cancer Institute, Cairo University. 
Negative control sections were prepared from the experimental tissue blocks not treated 
with the primary antibody. CD-105 staining was assessed blindly by evaluating the 
intensity of staining.  The staining was classified according to a four-grade scale (Bock et 
al., 2011): 0 absence of immune-staining or faint staining of few cells; 1 weak staining in 
most of the cells; 2‏ diffuse staining present in groups of cells; and 3‏ significant staining in 
most of the cells. The grade 0 and grade 1‏ expression of CD-105 were categorized as the 
low expression group, grade 2‏ and grade 3‏ as the high expression group. 
3.4.6 Image analysis 
Sections on hot spots were examined with conventional microscope (Olympus CX20) at 
250x original magnification connected to camera and computer. All the stained sections 
were examined by image analyzer computer system using the ImageJ software (NIH, 
version v1.45e, USA) capable of performing high speed digital image processing for the 
purpose of tissue measurements. Image J software (NIH, version v1.45e, USA) was 
calibrated and the image was opened on the computer screen for pre-analysis adjustments. 
For immunostaining intensity, global calibration was performed with values obtained 
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between 0 and 2.6 micron/pixel. Before calibration, pixel values are in gray level units in 
the range of 0-255. After calibration, pixel values are in OD. 
3.5 Tumors weight  
The effect of the treatments on tumors weight of EAC cells implanted as a solid tumor on 
the lower ventral side of Swiss albino mice was evaluated. At the end of the experiment, all 
tumors, 2-discs/animal, were punched out, weighed immediately, and the average weight 
was calculated. All tumors were then kept in 3.7% neutral buffered formalin for 
histological evaluation. 
 
3.6 Hematological studies 
On the 14
th
 day post-inoculation, the blood was withdrawn from the orbital sinus under 
light ether anesthesia and was collected on heparinized test tubes. The total and differential 
white blood cells (WBC), red blood cells (RBC), and the hemoglobin (Hb) content, were 
determined. 
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In-vitro study 
3.7 Cell culture methods 
 
3.7.1 Thawing of cells 
Cells were thawed in a 37
°
C water bath as quickly as possible. In order to minimize the 
toxic effect of the DMSO, 9 ml of fresh growth medium were added drop by drop to the 
cells suspended in 1 ml of freezing media. Thereafter, cells were pelleted by centrifugation 
at 1,200 rpm for 10 minutes. The cell pellet was re-suspended in the appropriate cell 
culture medium and seeded depending upon the desired cell density in tissue culture flasks 
and cultivated under standard conditions. 
 
3.7.2 Common cell culture methods 
The cells were grown in plastic 75 cm
2
 treated tissue culture flasks with vent Cap (BD 
Falcon, Germany). The flasks were kept in a standard tissue culture incubator (37
°
C, 95% 
relative humidity, and 5% CO2) and examined daily by a phase-contrast microscopy 
(Olympus CK2, Japan). The culture medium was changed twice weekly. Antibiotic 
mixtures of penicillin and streptomycin (Pen/Strep/fungizone) were used to protect cells 
from bacterial and fungal contamination. 
 
3.7.3 Passage of mammalian cells 
Almost confluent (80-90%) grown cells were passage into a new culture flask. First the 
medium was removed and cells were washed twice with 10 ml PBS. Approximately 5 ml 
of a trypsin/EDTA solution were added and the flask was incubated at 37°C for 3-5 min to 
dislodge the cells. Trypsinization was inhibited by addition of 5 ml serum containing 
growth medium. Cells were mixed well by pipetting up and down using 10 ml plastic 
pipette (Greiner bio-one, Germany) and transferred into a Falcon tube. The cells were 
pelleted by centrifugation (1200 rpm, 10 min.), re-suspended in growth medium and 
seeded at suitable density (splitting ratio 1:3 for MCF-7 and 1:5 for U-87). 
 
3.7.4 Freezing and storage of cells 
A 75 cm
2
 confluent culture flask was passaged as mentioned above. Cells were re-
suspended in 1 ml cold freezing medium supplied with 10% DMSO and 20% FBS then 
transferred with a sterile 1 ml pipette into cryotubes (Nunc, Germany). The cells were 
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stored for 2-3 hrs at -20°C, then overnight at -80°C prior to liquid nitrogen long term 
storage. 
 
3.7.5 Cell counting 
The cell number was determined using a Neubauer modified cell chamber. The cells were 
diluted with trypan blue and their numbers per ml were calculated by determining the 
average number of cells in the 4 large squares and multiplying by 10
4
 and the dilution 
factor. 
 
3.8 Cell proliferation assay  
 
3.8.1 Principle 
The cell viability was evaluated by using the resazurin dye. The resazurin method is 
simple, accurate and reproducible. The key component is the oxido-reduction indicator dye 
resazurin. Solutions of resazurin, prepared in balanced salt solutions without phenol red, 
are dark blue in color. Bioreduction of the dye by viable cells reduces the amount of its 
oxidized form [blue] and concomitantly increases the amount of its fluorescent 
intermediate [pink], indicating the degree of cytotoxicity caused by the test material. The 
amount of dye conversion in solution is measured fluorometrically in our study. 
3.8.2 Procedure 
At the end of the stimulation period with the tested drugs, the media were aspirated and 
100 µl of resazurin dye (10% (v/v) in growth media without phenol red) were added to 
each well for 4 hrs. The cell viability was determined by measuring the fluorescence at 
535/590 nm (excitation/emission) using FLUOstar multi-plate reader (BMG Labtech, 
Germany). 
 
3.8.3 Calculation of results 
Fluorescence values from vehicle-treated cells were considered as 100% of proliferation. 
The concentration at which the growth of cells was inhibited to 50% of the control (IC50) 
was obtained from this dose-response curve.      
 
Materials and Methods 
 
33 P a g e  |  
 
3.9 VEGF assay  
3.9.1 Principle 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for human VEGF has been pre-coated onto a microplate. 
Standards or samples were pipetted into the wells and any VEGF present was bounded by 
the immobilized antibody. After washing away any unbound substances, an enzyme-linked 
polyclonal antibody specific for VEGF was added to the wells. Following a wash to 
remove any unbound antibody-enzyme reagent, a substrate solution was added to the wells 
and color developed in proportion to the amount of VEGF bound in the initial step. The 
color development was stopped and the intensity of the color is measured. 
3.9.2 Preparation of samples 
The VEGF concentrations secreted by cells in the supernatants of the experimental group 
and the untreated control were quantified by collecting the cultured supernatant. The 
collected supernatant was centrifuged at 12,000 rpm for 15 minutes to remove cell debris. 
The clear supernatant was transferred to a new tube and then ELISA was performed 
according to the manufacturer’s instructions. 
 
3.9.3 Reagents 
 VEGF Microplate: 96 well polystyrene microplate (12 strips of 8 wells) coated with 
a mouse monoclonal antibody against VEGF.  
 VEGF Standard: 2000 pg/vial of recombinant VEGF in a buffered protein base 
with preservatives; lyophilized.  
 VEGF Conjugate: 21 ml/vial of a polyclonal antibody against VEGF conjugated to 
horseradish peroxidase with preservatives.  
 Assay Diluent RD1W: 11 ml/vial of a buffered protein base with preservatives.  
 Calibrator Diluent RD5K: 21 ml/vial of a buffered protein base with preservatives.  
 Wash Buffer Concentrate: 21 ml/vial of a 25-fold concentrated solution of buffered 
surfactant with preservatives.  
 Color Reagent A: 12 ml/vial of stabilized hydrogen peroxide.   
 Color Reagent B: 12 ml/vial of stabilized chromogen (tetramethylbenzidine).  
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 Stop Solution: 6 ml/vial of sulfuric acid.  
 Plate Covers: Adhesive strips.  
 
3.9.4 Assay procedure 
All reagents and samples were brought to room temperature before use.  
1-  All reagents, standard dilutions, and activated samples were prepared.  
2- 50 μL of assay diluent RD1W were added to each well.  
3- 200 μL of standard, control, or sample were added per well. The plate was gently 
tapped for one minute, and then covered with the adhesive strip provided and 
incubated for 2 hrs at room temperature. 
4- Each well was aspirated and washed with the washing buffer (400 μl), repeating the 
process for three times. After the last wash, any remaining wash buffer was removed 
by aspirating or decanting. The plate was inverted and blotted against clean paper 
towels. 
5- 200 μL of VEGF conjugate were added to each well. The plate was covered with a 
new adhesive strip and incubated for 2 hrs at room temperature.  
6- The aspiration/wash was repeated as in step 4. 
7- 200 μL of substrate solution were added to each well and incubated for 20 minutes at 
room temperature and protected from light. 
8- 50 μL of stop solution were added to each well. The plate was gently tapped to ensure 
thorough mixing. 
 
The optical density of each well was determined within 30 minutes, using a microplate 
reader (Metertech, Model: Σ960) set to 450 nm.  
 
3.9.5 Calculation of results  
A standard curve was constructed by plotting the mean absorbance for each standard on the 
Y-axis against the concentration on the X- axis and the best fit curve was drawn through 
the points on the graph.  
Intra-assay Precision 
Our data: Standard deviation: 0.4-3, coefficient of variation (%): 8-10. 
Manufacturer: Standard deviation: 1.9-18.4, coefficient of variation (%): 3.5-6.5. 
Recovery (%)  
Manufacturer: 95-111. 
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3.10 Apoptosis assay 
3.10.1 Principle 
The assay is based on the quantitative sandwich enzyme immunoassay principle using 
mouse monoclonal antibodies directed against DNA and histones. This allows the specific 
determination of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. 
1. Anti-histone antibody is adsorptively fixed on the wall of the microplate module, 
and nonspecific binding sites on the wall are saturated by treatment with blocking 
solution. 
2. The nucleosomes contained in the sample bind via their histone component to the 
immobilized anti-histone antibody. 
3. Anti-DNA-peroxidase reacts with the DNA part of the nucleosome. After removal 
of unbound peroxidase (POD) conjugate, the amount of peroxidase retained in the 
immunocomplex is photometrically determined with ABTS as the substrate. 
 
Figure XI: Schematic showing the principle of the Cell Death Detection ELISA (Taken from Roche catalog 
11544675001). 
 
3.10.2 Preparation of samples 
The floating and adherent cells were pelleted by centrifugation of the 96-well plate at 200 
X g for 10 minutes. The supernatant was gently removed and was discarded while the cell 
pellet was re-suspended with 200 µl incubation buffer and incubated for 30 minutes to lyse 
the cells. The lysate was centrifuged at 2000 X g for 10 minutes. The supernatant was 
transferred to clean Eppendorf tube. 
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3.10.3 Reagents 
 Microplate: 12 microplate modules (8 wells, each) and frame. 
 Anti-histone antibody: lyophilized vial. 
 Anti-DNA-POD: lyophilized vial. 
 Coating buffer: 2 ml, 10x conc. 
 Washing buffer: 40 ml, 10x conc. 
 Incubation buffer: 100 ml, ready-to-use-solution. 
 Substrate buffer: 15 ml, ready-to-use-solution. 
 ABTS substrate tablet: 3 x 5 mg tablets.  
 
 
3.10.4 Assay procedure 
All reagents and samples were brought to room temperature before use.  
1- All reagents and samples were prepared.  
2- 100 μL of coating solution were added to each well. The plate was covered with the 
adhesive strip provided and incubated over night at 2-8
o
C. 
3- Coating solution was removed by tapping. 
4- 200 μL of incubation buffer were added to each well. The plate was covered with a 
new adhesive strip and incubated for 30 minutes at room temperature.  
5- Each well was aspirated and washed with 250 μl washing solution, repeating the 
process three times.  
6- 100 μL of sample solution were added to each well. The plate was covered with a new 
adhesive strip and incubated for 90 minutes at room temperature. 
7- The aspiration/wash was repeated as in step 5. 
8- 100 μL of conjugate solution were added to each well. The plate was covered with a 
new adhesive strip and incubated for 90 minutes at room temperature. 
9- The aspiration/wash was repeated as in step 5. 
10-100 μL of substrate solution were added to each well and incubated on plate shaker at 
250 rpm for 20 minutes. 
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The optical density of each well was determined within 30 minutes, using a microplate 
reader FLUOstar (BMG Labtech, Germany) set to 405 nm.  
 
3.10.5 Calculation of results 
[(mU of the sample) – (mU of the background sample)] / (mU of the negative control 
sample)  
mU: absorbance[10
-3
], Background sample: samples without cells, Negative control 
sample: samples contain viable untreated cells.  
The values were normalized with protein contents in each sample using a micro BCA 
protein assay kit. 
Intra-assay Precision 
Standard deviation: 0.06-0.557, coefficient of variation (%): 1.3-7. 
 
3.11 Assay of caspase-3 activity 
3.11.1 Principle 
The treated cells were lysed to collect their intracellular contents. The cell lysate was tested 
for protease activity by the addition of a caspase-specific peptide that is conjugated to the 
color reporter molecule p-nitroaniline (pNA). The cleavage of the peptide by the caspase 
releases the chromophore pNA, which can be quantitated spectrophotometrically at a 
wavelength of 405 nm. The level of caspase enzymatic activity in the cell lysate is directly 
proportional to the color reaction. 
3.11.2 Preparation of samples 
After the end of the incubation period with drugs, the floating and adherent cells were 
centrifuged at 1200 rpm for 10 minutes. The supernatant was gently removed and was 
discarded while the cell pellet was lysed by the addition of the 25 µl cold lysis buffer per 
1x10
6
 cells. The cell lysate was incubated on ice for 10 minutes and then was centrifuged 
at 10,000 rpm for 1 minute. The supernatant was transferred to a new tube and was kept on 
ice. Protein estimation was performed using Bradford assay and 150 μg of protein was 
aliquoted from each sample and used for the assay.  
 
Materials and Methods 
34 P a g e  |  
 
3.11.3 Reagents 
 DEVD-pNA Substrate: 500 μL of 4 mM DEVD substrate peptide conjugated to p-
nitroaniline.  
 Lysis Buffer: 100 mL. 
 Reaction Buffer: 4 x 2.0 mL vials of 2X Reaction Buffer.  
 DTT: 400 μL of a 1 M solution of dithiothreitol.  
 Dilution Buffer: 100 mL. 
 
3.11.4 Assay procedure 
The assay was done using 96-well flat bottom microplate:  
1- 50 μL of distilled water (blank) or samples were added per well.  
2- 50 μL of reaction buffer were added to each well. 
3- 5 μL of caspase-3 colorimetric substrate (DEVD-pNA) were added to each well. The 
plate was incubated at 37
o
C for 2 hours. 
 
The optical density of each well was determined within 30 minutes, using a microplate 
reader FLUOstar (BMG Labtech, Germany) set to 405 nm.  
 
3.11.5 Calculation of results 
Caspase-3 activity was expressed as the change of activity (fold increase) compared to the 
control. 
Intra-assay Precision 
Standard deviation: 0.01-0.24, coefficient of variation (%): 1.3-7. 
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3.12 DNA isolation and electrophoresis 
 
3.12.1 DNA precipitation in ethanol 
Floating and adherent cells were pelleted by centrifugation at 1,200 rpm/ 10 min and lysed 
with 150 µl DNA lysis buffer at 37
o
C for 1 hr in the presence of proteinase K (0.1 mg/ml). 
Then 0.1 mg/ml of RNase were added to the lysates and incubated for 1 hr at 55
o
C. Ethanol 
precipitation was used for the purification of DNA. DNA was precipitated by adding 2 
volumes of cold 100% ethanol and 2 M of sodium acetate. DNA was washed with cold 
70% ethanol and dried for 10 min at room temperature. DNA was dissolved in 200 µl of 
TE-8 buffer and analyzed on a 1.5% agarose gel stained with ethidium bromide. 
3.12.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to resolve DNA constructs. Agarose gels were casted 
in TAE Buffer. DNA samples (100 ng) were diluted in 5x loading dye (Fermentase, 
Germany) before loading on agarose gels. Gels were run at 80 V in TAE buffer. The run 
was documented using the Chemi Doc system (BQLAB, Germany). 
 
3.13 Protein biochemical and Western blot methods 
3.13.1 Protein isolation and separation 
Floating and adherent cells were pelleted by centrifugation at 1,200 rpm/ 10 min/ 4°C and 
lysed with 100 µl RIPA lysis buffer on ice for 10 min in the presence of protease inhibitor 
cocktail (10 µl/ml) and sodium orthovandate (5 µl/ml). The lysates were cleared by 
centrifugation at 14,000 rpm/ 10 min/ 4°C. Protein estimation was performed using 
Bradford assay and 30 μg of protein were aliquoted from each sample and kept on ice. The 
samples were then boiled (95
o
 C) for 5 min with loading dye. The proteins were separated 
under reducing conditions in a 10% SDS polyacrylamide minigel. 
 
3.13.2 Estimation of protein concentration (Bradford method) 
Samples were diluted appropriately and the Bradford reagent was used to analyze the 
protein concentrations in duplicates. Different concentrations of BSA were used to 
construct the standard curve. 
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3.13.3 Estimation of protein concentration (BCA method) 
Samples were diluted appropriately and the BCA kit was used to analyze the protein 
concentrations in duplicates. Different concentrations of BSA were used to construct the 
standard curve. 
 
3.13.4 Immunoblotting 
After electrophoresis, proteins from a polyacrylamide gel were transferred according to the 
manufacturer’s instructions to a nitrocellulose membrane (8.5 cm x 13.5 cm) (Biorad, 
Germany) using the Trans-Blot turbo machine (BioRad, Germany). The membranes were 
blocked by incubation with the blocking solution for 3 hrs at room temperature. The blot 
was then incubated with appropriately diluted primary antibody solution overnight at 4°C. 
After the incubation period, the blots were washed 6 times each for 5 min with TBST and 
later incubated with appropriate secondary antibody conjugated to HRP for 1 hr. The blots 
were again washed with TBST and then the chemiluminescent peroxidase substrate was 
used to visualize protein bands. Signals were measured and analyzed using an ECL imager 
(BQLAB, Germany). 
 
3.13.5 Preparation of Nitrocellulose for re-probing (“Stripping”) 
The blots were stripped to remove primary and secondary antibodies. The blots were then 
re-probed with different antibodies. 
Procedure 
1. The membrane was added to a small plastic box which has a tight lid.  
2. The Harsh stripping buffer was added to cover the membrane (~10 ml). 
3. The membrane was incubated at 60°C for 30 minutes with some agitation. 
4. The membrane was washed with distilled water for 2 times each 5 minutes. 
5. Traces of β-mercaptoethanol will damage the antibodies. The membrane was 
washed extensively for 4 times each 5 minutes with TBST then, washed for another 
4 times each 5 minutes with TBS.  
6. The membrane was blocked using the blocking solution (3% BSA) and the 
procedure was repeated as described under the immunoblotting section (page 62). 
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4. Experimental design [Study design] 
The goals of the present study were achieved by carrying out eleven different sets of 
experiments: 
4.1 In-vivo antitumor activity and the involvement of CB-1 receptor 
Seventy male Swiss albino mice were used in this experiment. Each mouse was inoculated 
s.c. in the right flank with 2.5x10
6
 EAC cells in 100 µl saline. The animals were randomly 
divided into seven groups each consisting of 7-10 animals, non-responders were excluded, 
as follows: 
1. Group I: received DMSO (i.p.) and served as an EAC control group. 
2. Group II: received R-Met (i.p.) at a dose of 0.5 mg/kg. 
3. Group III: received OMDM-2 (i.p.) at a dose of 5 mg/kg.  
4. Group IV: received NIDA 41020 (i.p.) at a dose of 0.7 mg/kg. 
5. Group V: pretreated with NIDA 41020 (i.p.) at a dose of 0.7 mg/kg (30 minutes) 
followed by R-Met (i.p.) at a dose of 0.5 mg/kg.  
6. Group VI: pretreated with NIDA 41020 (i.p.) at a dose of 0.7 mg/kg (30 minutes) 
followed by OMDM-2 (i.p.) at a dose of 5 mg/kg.       
7. Group VII: received carboplatin (i.p.) at a dose of 5 mg/kg and serve as a 
reference group. 
 
All the treatments were given every third day starting from day 7 after tumor inoculation 
(when the tumor becomes palpable) for 6 doses. Table (III) summarizes the treatment 
regimen of the different groups.  
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Table (III): Summary of the in-vivo treatment regimen 
Group Treatment Dose 
I EAC control DMSO (100 µl) 
II R-Methanandamide 0.5 mg/kg 
III OMDM-2 5 mg/kg 
IV CB-1 Ant. (NIDA 41020) 0.7 mg/kg 
V CB-1 Ant. + R-Methanandamide 0.7 mg/kg + 0.5 mg/kg 
VI CB-1 Ant. + OMDM-2 0.7 mg/kg + 5 mg/kg 
VII Carboplatin 5 mg/kg 
 
Tumor volume was measured using digital Vernier caliber every third day throughout the 
experiment starting from the 7
th
 day post-inoculation (when the tumor become palpable). 
Relative tumor volume (RTV) and tumor growth time (TGT) time were calculated.  
Animals were monitored and mortality was recorded daily along the study period to 
calculate percentage survival of animals, mean survival time (MST), and the increased in 
the life span (%) among all animals. 
4.2 In-vivo anti-angiogenic activity and the involvement of CB-1 receptor 
Seventy male Swiss albino mice were used. Each mouse was inoculated i.d. at 2 sites 
bilaterally on the lower ventral side (after shaving this area) with 100 μl EAC 
suspension (2.5x10
6
 cells) on each site. 
 
Animals were randomly divided into seven groups (as mentioned in page 63) each 
consisting of 10 animals. The treatment was initiated 24 hours after tumor inoculation. 
Animals were given the drug regimens, mentioned under the antitumor experiment section, 
for a single time. The degree of angiogenesis was assessed by measuring the tumor 
vascular volume on day 3 as described in page 44 using Evans blue. 
Materials and Methods 
 
33 P a g e  |  
 
4.3 Time course effects on tumor weights, TGF-β1/CD-105 system and hematological 
parameters.  
In this experiment one hundred and forty seven mice were used. Each mouse was 
inoculated i.d. at 2 sites bilaterally on the lower ventral side (after shaving this area) with 
100 µl EAC suspension (2.5x10
6
 cells) on each site. Then, animals were randomly divided 
into seven groups (as mentioned before), 21 mice each. The treatment was initiated 24 
hours after tumor inoculation. Animals were given the drug regimens, mentioned under the 
antitumor experiment section, every third day. 
 
The 21 mice in each group were further subdivided into three subgroups A, B, and C, 
seven mice each. These subgroups were sacrificed on days 7, 14, and 21, respectively. 
Blood samples were collected through the orbital sinus, under light ether anesthesia, for the 
determination of serum TGF-β1 levels. After cervical dislocation, tumor discs were taken 
out and weighed then, fixed in 3.7% neutral buffered formalin for the assessment of the 
intra-tumoral expression of CD-105 receptor. The tumor weight, serum concentrations of 
TGF-β1 and expression of CD-105 receptor were evaluated as a time course on days 7, 14, 
and 21. 
 
In order to determine the influence of treatments on the hematological status of EAC-
bearing mice, a comparison was made among the treated groups on the 14
th
 day after 
inoculation. Blood was drawn from each mouse by the retro-orbital plexus method. The 
total, differential WBC, RBC, and Hb levels were determined. 
 
Two separate groups, each consisting of six mice served as Normal control group were 
used in the evaluation of serum TGF-β1 levels and in the hematological studies. 
The Pearson's equation was used for the determination of correlation coefficient between 
serum concentrations of TGF-β1 and tumor weights.  
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4.4 In-vitro anti-proliferative activity and the involvement of CB-1 and TRPV1 
receptors  
Two different cell lines were used in this experiment, MCF-7 and U-87 cells. The cells 
were seeded in flat bottom 96-well plate (Greiner bio-one, Germany) at a concentration of 
5x10
3
 cells/well in 100 µl growth medium supplemented with 10% FBS. Previous reports 
indicated that the presence of serum (i.e., FBS) affect the experimental outcomes of using 
cannabinoids in in-vitro models (Greenhough et al., 2007). Therefore, after 24 hrs of cell 
attachment in serum-containing medium, cells were serum starved for 24 hrs (starvation 
period). Thereafter cells were incubated with the treatment(s) for 24 hrs in serum free 
medium. Control cells were treated with the solvent control DMSO (0.5%). Table (IV) 
summarizes the treatment protocol for each cell line. 
 
The dehydrogenase activity was fluorometrically determined by measuring the reduction of 
resazurin (blue, non-fluorescent) to resorufin (pink, highly fluorescent) as described in 
page 54. Each drug concentration was examined in duplicates in five independent 
experiments. 
Table (IV): Summary of the in-vitro treatment regimen 
Treatment MCF-7 U-87 
OMDM-2 2.5, 5, 10, 20, 40, 80 µM 0.625, 1.25, 2.5, 5, 10, 20, 40, 80 µM 
NIDA41020 0.2 µM* 0.2 µM* 
Capsazepine 1 µM* 1 µM* 
Curcumin 5, 10, 20, 30, 40, 80 µM 5, 10, 20, 30, 40, 80 µM 
Temozolomide ------------------------------------ 50, 100, 200, 300, 400 µM 
Paclitaxel 10, 100, 1000, 10000, 100000 nM ------------------------------------------ 
 
* pre-incubated for 30 minutes before the addition of OMDM-2 
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4.5 Effect of OMDM-2 on VEGF level 
The MCF-7 cells were seeded in 6-well plate at a concentration of 1x10
5
 cells/well in 1 ml 
of growth medium supplemented with 10% FBS. The cells were incubated at 37
o
C in a 
humidified incubator with 5% CO2 for 24 hrs. After washing twice with PBS, the cells 
were exposed to the IC50 of OMDM-2 and incubated for 24 hrs. After the end of the 
stimulation period, the culture supernatant of each sample was transferred to 1.5 ml 
Eppendorf tube. The cellular debris were pelleted by centrifugation (12000 rpm, 15 min), 
the resultant clear supernatant was used for estimation of VEGF level as discussed before 
(page 55). 
 
4.6 Role of apoptosis in the anti-proliferative activity of OMDM-2  
The cells were seeded in 96-well plate at a concentration of 2x10
4
 cells/well in 100 µl of 
growth medium supplemented with 10% FBS. The cells were allowed to attach by 
incubation at 37
o
C in a humidified incubator with 5% CO2 for a period of 24 hr. Then, the 
growth medium was removed and replaced by 100 µl/well fresh serum-free medium after 
washing twice with PBS. After 24 hrs, the medium was aspirated and the cells were treated 
with 3 different concentrations of OMDM-2 which had been selected based on the results 
of the cell viability experiments. After the end of the stimulation periods (8, 12, 24 hrs), 
floating and adherent cells were pelleted by centrifugation (200 X g, 10 min) and the 
resultant pellet was used for the estimation of apoptosis as discussed before (page 57). 
 
4.7 Role of caspase-3 in the anti-proliferative activity of OMDM-2 
U-87 cells were seeded in 35x10 mm dish (DB Falcon, Germany) at a concentration of 
1x10
6
 cells in 1 ml of growth medium supplemented with 10% FBS. The cells were 
allowed to attach by incubation at 37
o
C in a humidified incubator with 5% CO2 for a 
period of 24 hrs. Then, the growth medium was removed and replaced by 1 ml of fresh 
serum-free medium after washing twice with PBS. After 24 hrs the medium was aspirated 
and the cells were treated with 3 different concentrations of OMDM-2 which had been 
selected based on the results of the cell viability experiments. At the end of the stimulation 
periods (8, 12, 24 hrs), the floating cells in the media of each sample were transferred to 
1.5 ml Eppendorf tube. The attached cells were detached using 500 µl trypsin for 5 min. 
The detached cells were transferred to the Eppendorf tube corresponding to each sample. 
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Cells were pelleted by centrifugation (1200 rpm, 10 min) the resultant pellet used for 
estimation of the activity of caspase-3 as discussed before (page 59). 
 
4.8 Apoptosis-DNA ladder assay (DNA laddering)  
U-87 cells were seeded in 35x10 mm dish at a concentration of 0.5x10
6
 cells in 1 ml of 
growth medium supplemented with 10% FBS. The cells were allowed to attach by 
incubation at 37
o
C in a humidified incubator with 5% CO2 for a period of 24 hr. Then, the 
growth medium was removed and replaced by 1 ml of fresh serum-free medium after 
washing twice with PBS. After 24 hrs the medium was aspirated and the cells were treated 
with 20 µM of OMDM-2. At the end of the stimulation periods (8, 12, 24 hrs), the floating 
cells in the media of each sample were transferred to 1.5 ml Eppendorf tube. The attached 
cells were scrapped using 500 µl cold PBS. The detached cells were transferred to the 
Eppendorf tube corresponding to each sample. Cells were pelleted by centrifugation (1200 
rpm, 10 min) the resultant pellet used for estimation of DNA fragmentation as discussed 
before (page 61). Two positive controls were used, H2O2 32 µM (incubated for 24 hrs 
followed by 3 cycles of freeze-thaw lysis) as a positive control for necrosis while paclitaxel 
500 nM (incubated for 72 hrs) represents a positive control for apoptosis.  
 
4.9 Effect of OMDM-2 on morphology of cells 
After exposure to different concentrations of OMDM-2 for 24 hrs, the cells were observed 
under an inverted microscope from Olympus (Olympus CK2, Japan). Pictures were taken 
with a Coolpix camera from Nikon (Germany).  
 
4.10 Signal cascade pathways induced by OMDM-2 using Western blot analysis 
 
The cells (MCF-7 or U-87) were seeded in 35x10 mm dish at a concentration of 1x10
6
 
cells in 1 ml of growth medium supplemented with 10% FBS. The cells were allowed to 
attach by incubation at 37
o
C in a humidified incubator with 5% CO2 for a period of 24 hrs. 
Then, the growth medium was removed and replaced by 1 ml of fresh serum-free medium 
after washing twice with PBS. After 24 hrs the medium was aspirated and the cells were 
treated with 3 different concentrations of OMDM-2 which had been selected based on the 
results of the cell viability experiments. At the end of the stimulation period, the floating 
and adherent cells were collected and centrifuged at 1200 rpm/ 10 min/ 4°C. The resultant 
pellet used for protein separation as discussed before (page 61). 30 μg of proteins were 
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analyzed for the total and the phosphorylated extracellular regulated kinase (ERK1/2), and 
AKT using Western blot technique.  
 
 
4.11 New chemotherapeutic cocktails (combination study) 
Resazurin assay as described before (page 54) was used to evaluate the inhibitory efficacy 
of different combination of drugs. To demonstrate whether there are synergistic, additive 
or antagonistic effects, cells were treated with different ratios of drugs for each 
combination as shown in Table (V). The isobole analyses, the combination index (CI) and 
the dose reduction index (DRI) were used to evaluate each combination (Chou and 
Talalay 1983; Menéndez et al., 2001, Barrio et al., 2013).  
 
4.11.1 Isobol analysis 
The drug concentration of single or combined regimens that produced a 50% or 70% 
inhibitory effects were used as coordinates to construct isobolograms. The diagonal 
straight line connecting the IC50 or IC70 of single drugs represents the theoretical line of 
additivity for a continuum of different fixed dose ratios. When the combination is 
synergistic, the isobol (the line joining the points that represent the combination with the 
same 50% or 70% inhibitory effect, including the equally effective concentrations of single 
drugs used alone) is a concave curve, and antagonistic combination yields a convex curve. 
 
4.11.2 Combination index (CI) 
The CI was calculated by the CompuSyn software based on the Chou-Talalay equation, 
which takes into account both potency (Dm or IC50) and the shape of the dose-effect 
curve. Briefly, CI < 1, CI = 1, and CI > 1 indicate synergism, additive effect and 
antagonism, respectively.  
 
4.11.3 Dose reduction index (DRI)  
Representing the measure of how much the dose of each drug in a combination may be 
reduced at a given effect level compared with the doses of each drug alone. 
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Table (V): Summary of combinations ratios 
Combinations 
Combination ratio 
MCF-7 U-87 
OMDM-2:Curcumin 
1:8, 1:4, 1:2, 1:1, 2:1, 
4:1 
1:32,1:16, 1:8, 1:4, 1:2, 1:1, 2:1, 
4:1 
OMDM-2: Paclitaxel 
4:1, 20:1, 100:1, 500:1, 
2500:1 
--------------------------------- 
OMDM-2:Temozolomide -------------------------- 
1:320, 1:160, 1:80, 1:40, 1:20, 
1:10, 1:5, 1:2.5 
 
4.12 Data analysis and statistics 
Data were expressed as mean ± standard error of the mean (S.E). Statistical analysis was 
performed using SPSS software, version 16. Data were analyzed for significant differences 
in tumor volume, relative tumor volume, TGT, tumor weights, MST, serum levels of TGF-
β1, and hematological parameters by using one-way analysis of variance (ANOVA), 
followed by Bonferroni post-hoc test for multiple comparisons.  
Immunohistochemistry for CD-105 was analyzed using Chi-square test. For the survival 
time of animals, Kaplan-Meier curves were established for each group, and survival was 
compared using Log rank test. For in-vitro studies, data were analyzed for statistical 
significance by using t-test. 
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5. Results 
5.1 Antitumor activity 
The antitumor effects of the systemic administration of R-Met or OMDM-2 either 
alone or combined with CB-1 blocker pretreatment, NIDA 41020, were determined 
by assessing the changes in tumor volume, relative tumor volume (RTV), tumor 
growth time (TGT). The antitumor effect of carboplatin was determined as a 
reference standard. 
5.1.1 Effect on solid tumor volume  
The mice treated with vehicle (DMSO) alone developed subcutaneous tumors, the 
size of which was around 700 mm
3 
at the end of the experiment (i.e. 25 days).  
The administration of either R-Met or OMDM-2, every third day for 6 doses starting 
from day 7 post-inoculation, were able to significantly reduce the solid tumor volume 
as compared to the EAC control group (Figures 1, 2). Similarly, the treatment with 
the reference standard, carboplatin, showed a significant antitumor activity (Figures 
1, 2). On the other hand, the treatment with CB-1 blocker (0.7 mg/kg, i.p.), NIDA 
41020, per se did not affect the tumor volume compared to the control group (Figures 
1, 2). 
 
Meanwhile, the pretreatment with NIDA 41020 significantly antagonized the 
antitumor activity of R-Met (Figure 1), an effect that was not observed in OMDM-2 
treated group, where OMDM-2 maintained its antitumor potential (Figure 2).   
 
5.1.2 Effect on relative tumor volume 
The systemic administration of OMDM-2 (5 mg/kg, i.p.) or R-Met (0.5 mg/kg, i.p.) 
resulted in a significant decrement in the relative tumor volume by 38% and 28%, 
respectively at the end of the experiment compared to the untreated control group 
(Figure 1, 2). The treatment with the CB-1 blocker (0.7 mg/kg, i.p.), NIDA 41020, 
per se did not affect the RTV compared to EAC control group. 
 
NIDA 41020 pretreatment significantly antagonized the reducing effect of R-Met on 
RTV (Figure 1). While the pretreatment with NIDA 41020 did not antagonize the 
reducing effect of OMDM-2 on RTV; where OMDM-2 maintained its antitumor 
potential and reduced the tumor volume by 31% as efficaciously as carboplatin 
(Figure 2).   
Results 
  P a g e | 72 
 
5.1.3 Effect on tumor growth time (TGT) 
The administration of either R-Met (0.5 mg/kg, i.p.) or carboplatin (5 mg/kg, i.p.) 
significantly prolonged (Table 1) the TGT required to reach three folds the initial 
tumor volume by 43% and 40%, respectively (Figure 3). They also were able to 
inhibit the size of tumor to reach four folds the initial tumor volume.  
 
OMDM-2 (5 mg/kg, i.p.) administration significantly prolonged the TGT required to 
double the initial tumor volume from the seventh day post inoculation by 122% 
(Table 1 & Figure 3). Successfully, the tumor size of OMDM-2-treated mice did not 
reach three folds the initial volume and consequently four folds.  
 
The pretreatment with NIDA 4120 (CB-1 blocker) significantly antagonized the 
prolongation effect of R-Met on the tumor growth tripling and quadrupling times and 
also antagonized the prolongation effect of OMDM-2 on the tumor growth tripling 
time (Table 1 & Figure 3).  
 
Tumor growth doubling time of OMDM-2 group pretreated with NIDA 41020 tended 
to be prolonged by about 50% as compared to EAC control group; however this 
prolongation was not statistically significant. On the other hand, NIDA 41020 was 
unable to antagonize the effect of OMDM-2 on tumor growth quadrupling time 
(Table 1 & Figure 3). 
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Figure (1): Effect of the systemic administration of R-Met and/or CB-1 
antagonist on the solid tumor volume in EAC-bearing mice. 
 
Effect of i.p injection of R-Methanandamide (0.5 mg/kg) either alone or in combination with CB-1 
antagonist, NIDA 4120, pretreatment (0.7 mg/kg) on Ehrlich solid tumor volume [upper panel] and 
on relative tumor volume {(V/Vcontrol) x100} [lower panel]. Mice were inoculated s.c in the right 
flank with Ehrlich ascites carcinoma cells (2.5x106 cells/mouse). On day 7 post-inoculation mice 
bearing solid Ehrlich carcinoma were injected with the drugs every third day for six doses till day 
21. The changes in the total volume (mm3) were determined on day 7 until day 25, and the results 
were compared with the EAC-bearing mice. Values are expressed as mean ± S.E for n=7-10 mice 
[upper panel]. Values are expressed as mean tumor volumes of treated groups relative to mean 
tumor volume of EAC-bearing mice (control group) [lower panel]. All the data were analyzed using 
ANOVA followed by Bonferroni post-hoc test for multiple comparisons of means.  
* Significantly different from EAC control group at p≤ 0.05. ** Significantly different from EAC 
control group at p≤ 0.01. 
#
 Significantly different from the individual corresponding treatment (i.e. 
without CB-1 antagonist) at p≤ 0.05. 
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Figure (2): Effect of the systemic administration of OMDM-2 and/or CB-1 
antagonist on the solid tumor volume in EAC-bearing mice. 
 
Effect of i.p injection of OMDM-2 (5 mg/kg) either alone or in combination with NIDA 4120 (CB-
1 antagonist) pretreatment (0.7 mg/kg) on Ehrlich solid tumor volume [upper panel] and on relative 
tumor volume {(V/Vcontrol) x100} [lower panel]. Mice were inoculated s.c in the right flank with 
Ehrlich ascites carcinoma cells (2.5x106 cells/mouse). On day 7 post-inoculation mice bearing solid 
Ehrlich carcinoma were injected with the drugs every third day for six doses till day 21. The 
changes in the total volume (mm3) were determined on day 7 until day 25, and the results were 
compared with the EAC-bearing mice. Values are expressed as mean ± S.E for n=7-10 mice [upper 
panel]. Values are expressed as mean tumor volumes of treated groups relative to mean tumor 
volume of EAC-bearing mice (control group) [lower panel]. All the data were analyzed using 
ANOVA followed by Bonferroni post-hoc test for multiple comparisons of means. ** Significantly 
different from EAC control group at p≤ 0.01. *** Significantly different from EAC control group at 
p≤ 0.001.   
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Table (1): Effect of the systemic administration of R-Met or OMDM-2 
with/without CB-1 blocker pretreatment on the tumor growth time (TGT) in 
EAC-bearing mice  
 
Tumor growth time (TGT) 
(Days)  
Group 
Tumor 
doubling time 
Tumor tripling 
time 
Tumor 
quadrupling time 
EAC-Control 6.3±0.7 12.1±0.9 15.9±0.8 
R-Met 9±1.2 17.3±0.7* ---------- 
OMDM-2 14±1.4** ---------- ---------- 
CB-1 Antagonist  6.5±1.2 12±1.3 16.5±0.4 
R-Met+ CB-1 Ant. 6±1.6 10.3±1.6
#
 15±1.3 
OMDM-2+CB-1 Ant. 9.5±2.2 12.5±1.3 ---------- 
Carboplatin 10.5±1.7 17.2±0.5* ---------- 
 
TGT is the tumor growth time (days; mean ± S.E) required to reach 2-(doubling), 3-(tripling), or 4-
(quadrupling) folds the initial tumor volume. All data were analyzed using ANOVA followed by 
Bonferroni post-hoc test for multiple comparisons of means. * Significantly different from EAC 
control group at p≤ 0.05. ** Significantly different from EAC control group at p≤ 0.01.  
#
 Significantly different from individual corresponding treatment (i.e. without CB-1 antagonist) at 
p≤ 0.05. 
 
---------- Means didn't reach the required tumor volume.   
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Figure (3): Effect of the systemic administration of R-Met or OMDM-2 
with/without CB-1 blocker pretreatment on the percentage of increase in tumor 
growth time (TGT). 
 
Effect of i.p injection of R-Methanandamide (0.5 mg/kg) or OMDM-2 (5 mg/kg) either alone or in 
combination with NIDA 4120 (CB-1 antagonist) pretreatment (0.7 mg/kg) on  the percentage increase 
in tumor growth time (TGT) from control to reach double, triple, or quadruple the initial tumor volume 
in EAC bearing Swiss albino mice. Mice were inoculated s.c in the right flank with Ehrlich ascites 
carcinoma cells (2.5x106 cells/mouse). On day 7 post-inoculation mice bearing solid Ehrlich carcinoma 
were injected with the drugs every third day for six doses till day 21. Values are expressed as 
percentage from EAC control. All data were analyzed using ANOVA followed by Bonferroni post-hoc 
test for multiple comparisons of means. * Significantly different from EAC control group at p≤ 0.05. 
** Significantly different from EAC control group at p≤ 0.05.  
#
 Significantly different from individual 
corresponding treatment (i.e. without CB-1 antagonist) at p≤ 0.05. 
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5.2 Survival study 
5.2.1 Effect on survival of animals (%) 
The change in percent survival of animals was recorded daily for a period of 89 days 
(when the last animal died) following tumor inoculation. On day 37, there was a 50% 
survival in the EAC control group; whereas R-Met, OMDM-2 in addition to OMDM-
2 group pretreated with NIDA 41020 (CB-1 blocker) showed 100% survival, while 
both R-Met group pretreated with NIDA 41020 and carboplatin showed 71% survival 
(Table 2 & Figure 4). The control EAC-bearing mice showed zero% survival after 56 
days of the tumor inoculation. On the same day, a 45% survival was noted in R-Met 
and OMDM-2 treated groups (Table 2 & Figure 4). While both OMDM-2 and R-Met 
groups pretreated with NIDA 41020 maintained 70% and 30% survival, respectively 
(Table 2 & Figure 4). Also, on the same day (i.e. day 56) carboplatin showed only 
15% survival of animals. 
 
5.2.2 Effect on mean survival time (MST) 
The mean survival time (MST) in the EAC-control group was 37.2±4.3 days. 
OMDM-2 succeeded to significantly increase MST to reach 59.11±4.9. On the other 
hand, R-Met or carboplatin tended to increase MST to reach 52±3.9 and 50±7.2, 
respectively but this increment did not reach statistical significance (Table 3).   
 
OMDM-2 group pretreated with NIDA 41020 showed a significant increment in MST 
to reach 59.4±2.5, while NIDA 41020 pretreatment counteracted the effect of R-Met 
on the prolongation of survival time (Table 3). 
 
5.2.3 Effect on life span (%ILS) 
Parallel to the results of MST, R-Met, OMDM-2, and carboplatin were able to 
enhance the life span of EAC-bearing mice by more than 25% compared to EAC-
control group. Also, OMDM-2 group pretreated with NIDA 41020 showed a 
significant enhancement in the life span of animals. Groups treated with the OMDM-2 
either alone or its combination with NIDA 41020 pretreatment showed the highest 
%ILS, 59.5, and 60.5%, respectively (Table 3). 
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Table (2): Number of survived animals in all treatment groups 
 
 
Starting number of animals in each group was 7-10. Number of animals survived daily was recorded in 
all groups. Experiment was extended to day 89 when the last animal died. The highlighted lines 
indicate 50% and 0% survival of EAC control.  
 
 
 
 
 
Time (Days) 
EAC R-Met OMDM-2 CB-1 Ant. 
 
R-Met 
+ CB-1 Ant. 
 
 
OMDM-2  
+CB-1 Ant. 
 
Carboplatin 
1 10 9 9 7 7 7 7 
15 10 9 9 7 6 7 7 
18 10 9 9 7 5 7 7 
20 9 9 9 7 5 7 7 
22 8 9 9 7 5 7 7 
23 7 9 9 7 5 7 7 
25 6 9 9 7 5 7 7 
30 6 9 9 7 5 7 6 
32 6 9 9 6 5 7 6 
37 5 9 9 6 5 7 5 
38 5 7 9 6 5 7 5 
39 5 7 9 5 5 7 5 
40 5 7 8 5 5 7 5 
42 5 6 8 4 5 7 4 
43 4 5 8 4 5 7 4 
44 4 5 8 4 4 7 4 
46 3 5 7 4 3 7 3 
48 2 5 6 3 3 6 3 
51 2 5 6 2 3 5 3 
52 1 5 6 0 2 5 2 
53 1 5 6   2 5 1 
55 1 4 4   2 5 1 
56 0 4 4   2 5 1 
58   3 4   2 5 1 
61   2 4   2 3 1 
62   2 2   1 3 1 
63   2 2   0 2 1 
64   2 2     1 1 
66   0 2     1 1 
67     2     0 1 
82     0       1 
89       0 
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Figure (4): Effect of R-Met (0.5mg/kg, i.p), upper panel; or OMDM-2 (5mg/kg, 
i.p), lower panel, alone and in combination with CB-1 blocker (0.7mg/kg, i.p) on 
cumulative survival of EAC-bearing mice. 
Cumulative survival of animals = number of living animals/initial total number of animals. Experiment 
was extended to day 89 when the last animal died in all groups. Survival curves were constructed 
according to the Kaplan-Meier method and statistical significance was determined using Log rank test.  
Log Rank = 0.216 
Log Rank = 0.008 
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Table (3): Effect of systemic administration of R-Met or OMDM-2 with/without 
CB-1 blocker pretreatment on mean survival time (MST)  
Group MST (days) %ILS 
EAC-Control 37±4.3  
R-Met 52±3.9 40.5
●
 
OMDM-2 59±4.9* 59.5
●
 
CB-1 Antagonist 45±2.9 21.6 
R-Met+ CB-1 Ant.  43±7.3 16.2 
OMDM-2+CB-1 Ant. 59.4±2.5* 60.5
●
 
Carboplatin 50±7.2 35.1
●
 
 
MST (mean survival time) = sum of survival days of all mice in each group/total number of mice in 
this group. ILS (increase in life span) = [(MST of treated group/MST of control group)-1]. 7-10 
mice were used in each group. Values are expressed as mean ± S.E All data were analyzed using 
ANOVA followed by Bonferroni post-hoc test for multiple comparisons of means. * Significantly 
different from EAC control group at p≤ 0.05. ● ILS > 25%. 
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5.3 Angiostatic activity (vascular permeability) 
In this experiment, the anti-angiogenic effects of R-Met or OMDM-2 either alone or 
in combination with NIDA 41020 (CB-1 blocker) pretreatment were investigated. The 
degree of angiogenesis was assessed by measuring the tumor vascular volume using 
Evans blue; the percentage of angiogenesis was calculated as previously explained 
(page 44).  
 
The administration of R-Met or OMDM-2 significantly reduced the percentage of 
angiogenesis in the solid tumors by about 50% and 40%, respectively (Figure 5). This 
effect was antagonized in the R-Met-treated group but not in the OMDM-2-treated 
group by the pre-treatment with NIDA 41020 (Figure 5). Surprisingly NIDA 41020 
also exerted a significant, albeit small, anti-angiogenic action per se (Figure 5). 
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Figure (5): Effect of the systemic administration of R-Met or OMDM-2 
with/without CB-1 blocker pretreatment on the percentage of angiogenesis in 
Ehrlich solid tumor. 
Effect of i.p injection of R-Methanandamide (0.5 mg/kg) or OMDM-2 (5 mg/kg) either alone or in 
combination with NIDA 41020 (CB-1 antagonist) pretreatment (0.7 mg/kg) on the percentage of 
angiogenesis. Mice were inoculated intradermally (i.d) at 2 sites bilaterally on the lower ventral side with 
Ehrlich ascites carcinoma cells (2.5x106 cells/0.1 ml) on each site. The treatment was initiated 24 hours 
after tumor inoculation for a single dose. The degree of angiogenesis was assessed by measuring the 
tumor vascular volume on day 3 using Evans blue method. Each value represents the mean ± S.E of n= 10 
mice. All data were analyzed using ANOVA followed by Bonferroni post-hoc test for multiple 
comparisons of means. Results are expressed as percentage of EAC control.  
* Significantly different from EAC control group at p≤ 0.05. # Significantly different from the individual 
corresponding treatment (i.e. without CB-1 antagonist) at p≤ 0.05. 
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5.4 Role of TGF-β1/CD-105 system 
In the current study, the in-vivo effects of R-Met or OMDM-2 either alone or combined 
with NIDA 4120 (CB-1 blocker) pretreatment on the serum levels of TGF-β1 and on the 
expression of endoglin (CD-105) receptor in tumor tissue were assessed as a time 
course on days 7, 14, and 21 post-inoculation. 
5.4.1 Serum levels of TGF-β1  
EAC induced a significant and persistent increase in the serum concentrations of 
TGF-β1 compared to the normal control group on days 7, 14, and 21 (Figure 6). On 
day 7, both R-Met and OMDM-2 significantly increased the serum concentrations of 
TGF-β1 compared to the EAC-control group by about 47% (Figure 6).  
Interestingly, a pre-treatment with NIDA 41020 significantly antagonized the 
enhancing effect of R-Met on the TGF-β1 concentrations on day 7.  The decrease was 
about 25% followed by a non-significant increase on day 21 compared to the R-Met-
treated group. In case of OMDM-2, the CB1-blocker, NIDA 41020, significantly 
augmented the inducing effect of OMDM-2 on the TGF-β1 concentrations on day 7 
and increased it by about 26% compared to the OMDM-2-treated group. Interestingly 
at day 7 NIDA 41020 per se decreased the elevated level of TGF-β1 in EAC-bearing 
mice (Figure 6). 
On days 14 and 21 post-inoculation, individual treatments with R-Met, OMDM-2 or 
NIDA 41020 did not affect the elevated serum levels of TGF-β1 compared to the 
EAC-control group (Figure 6). Carboplatin did not affect the elevated levels of TGF-
β1 at all time points compared to the EAC-control group (Figure 6). 
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Figure (6): Effect of R-Met or OMDM-2 with/without CB-1 blocker 
pretreatment on the serum levels of TGF-β1 in EAC-bearing mice. 
Effect of i.p injection of R-Methanandamide (0.5 mg/kg) or OMDM-2 (5 mg/kg) either alone or in 
combination with CB-1 blocker pretreatment, NIDA 41020, (0.7 mg/kg) on serum levels of TGF-β1. 
Mice were inoculated i.d. in the lower ventral side with EAC cells (2.5x106 cells/mouse). 24 hrs post-
inoculation, mice bearing solid Ehrlich carcinomas were treated with the drugs twice a week for 1, 2 or 
3 weeks (total 6 doses). The time course levels of TGF-β1 were determined using ELISA. Each value 
represents the mean ± S.E of n= 6-7 mice. All data were analyzed using ANOVA followed by 
Bonferroni post hoc-test for multiple comparisons of means. ● Significantly different from normal 
group at p≤ 0.05. * Significantly different from EAC control group at p≤ 0.05. # Significantly different 
from the individual corresponding treatment (without CB-1 antagonist) at p≤ 0.05. 
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5.4.2 Intra-tumoral expression of endoglin receptor (CD-105) 
On day 7 post-inoculation; a significant difference in tissue CD-105 expression was 
observed among the 7 groups using Chi-square test; while, the evaluation of intra-
tumoral CD-105 on days 14 and 21 post-inoculation showed a poor expression of the 
receptor in all groups including the EAC-control group (Table 4). Expression of tissue 
CD-105 was confirmed by the presence of brown stained cells in EAC tissue (Figure 
7).   
The tissue expression of CD-105 was up-regulated among all mice in EAC control 
group (Table 4, Figure 7). The systemic administration of R-Met (0.5 mg/kg) was 
able to reduce the percentage of high expression of CD-105 in EAC-bearing mice to 
reach 33% (Table 4, Figure 7). While, OMDM-2-treated group showed only 17% 
moderate expression and 83% poor expression of tissue CD-105 (Table 4, Figure 7). 
On the other hand, the systemic administration of CB-1 blocker per se, NIDA 41020, 
did not affect the up-regulated expression of CD-105 in EAC-bearing mice as the 
percentage of CD-105-rich tumors remained 100% (Table 4, Figure 7). 
 
Meanwhile, the CB-1 blocker completely antagonized the down-regulating effect of 
R-Met; as this group showed 100% high expression (Table 4, Figure 7). On the other 
hand, the pretreatment with CB-1 blocker, NIDA41020 increased the percentage of 
poor expression to reach 100% in OMDM-2-treated group as efficaciously as 
carboplatin (Table 4, Figure 7).         
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Table (4): Effect of the systemic administration of R-Met or OMDM-2 
with/without CB-1 blocker pretreatment on the number of animals exhibiting 
different grades of intratumoral CD-105 assessed immunohistochemically on day 
7 post-inoculation of EAC cells in Swiss albino mice  
            Grades  
 
Groups         
Grade 0 
≤10% 
Grade 1 
11-30% 
Grade 2 
31-50% 
Grade 3 
<50% 
%CD-105 
rich tumors* 
EAC-Control 0 0 0 6 100 
R-Met 0 4 2 0 33
*
 
OMDM-2 0 5 1 0 17
*
 
CB-1 Ant. 0 0 0 6 100 
R-Met+CB1 Ant. 0 0 0 6 100 
OMDM-2+CB1 Ant. 0 6 0 0 0
*
 
carboplatin 0 6 0 0 0
*
 
 
* CD-105 rich tumors include specimens with moderate and strong expression of CD-105 (Grades 2 
and 3, respectively). Chi-square test was performed to compare CD-105 immunohistochemical 
expressions   
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Figure (7): Representative samples of CD-105 immunostaining. 
Effect of R-Met or OMDM-2 systemic administration with/without CB-1 blocker pretreatment, 
NIDA41020, on the cytoplasmic expression of CD-105 on day 7 post-inoculation of EAC cells in 
Swiss albino mice. CD-105 appears to be expressed with a ground glass pattern in the cytoplasm of 
breast tumor cells (brown stain). Meyer’s hematoxylin counterstain (×250 original magnification)                                                                                                             
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5.5 Effect on the tumor weights 
The systemic administration of either OMDM-2 or carboplatin led to a significant 
reduction in tumor weights on days 7, 14 and 21 post-inoculation as compared to the 
EAC-group (Figure 8). The R-Met-treated group showed similar results on days 7 
and 21 post-inoculation while on day 14 results did not reach statistical significance 
(Figure 8).  Blocking of CB-1 receptor significantly antagonized the tumor reducing 
ability of R-Met at both time points (Figure 8). In case of OMDM-2, the CB-1 
blocker, NIDA41020, pre-treatment did not alter its tumor reducing activity on days 7 
and 21.  
 
However, on day 14 a pre-treatment with the CB-1 blocker, NIDA4102, decreased the 
antitumor activity of OMDM-2 without reaching statistical significance compared to 
the OMDM-2-treated group.    
 
On the other hand, the treatment with NIDA41020 (0.7 mg/kg, i.p.) per se did not 
affect the tumor weights at all time points along the experiment period as compared to 
the EAC-control group (Figure 8). 
 
5.6 Correlation between serum TGF-β1 and tumor weights 
The Pearson correlation coefficient was determined for the relationship between 
serum concentrations of TGF-β1 and tumor weights in the EAC model.  On day 7 
post-inoculation a negative association was found (rp = - 0.8), however, without 
reaching statistical significance (p=0.052) (Figure 9). The results indicated that on the 
progression of tumor (days 14 and 21) this association seems to be lost (rp = - 0.5 and 
- 0.15, respectively) (Figure 9). 
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Figure (8): Effect of the systemic administration of R-Met or OMDM-2 
with/without CB-1 blocker pretreatment on the tumor weight of EAC  
Effect of i.p injection of R-Methanandamide (0.5 mg/kg) or OMDM-2 (5 mg/kg) either alone or in 
combination with CB-1 blocker pretreatment, NIDA 41020, (0.7 mg/kg) on tumor weight. Mice were 
inoculated in the lower ventral side with Ehrlich ascites carcinoma cells (2.5x106 cells/mouse). 24 hrs 
post-inoculation, mice bearing solid Ehrlich carcinomas were treated with the drugs twice a week for 1, 
2, or 3 weeks and the change in tumor weights (mg) were determined. Each value represents the mean 
± S.E of n= 7 mice. All data were analyzed using ANOVA followed by Bonferroni post-hoc test for 
multiple comparisons of means. * Significantly different from EAC control group at p≤ 0.05. ** 
Significantly different from EAC control group at p≤ 0.01. *** Significantly different from EAC 
control group at p≤ 0.001.# Significantly different from individual corresponding treatment (without 
CB-1 antagonist) at p≤ 0.05.  
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Figure (9): Correlation between the serum levels of TGF-β1 and the tumor weights in EAC-
bearing mice treated with R-Methanandamide (0.5 mg/kg, i.p.) or OMDM-2 (5 mg/kg, i.p.) and their 
combination with CB-1 blocker, NIDA 41020, (0.7 mg/kg, i.p.) on days 7, 14 and 21 (a, b and c, 
respectively) post-inoculation. r denotes the Pearson's correlation coefficient obtained for the linear 
regression line. r did not reach significance.  
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5.7 Effect on hematological status 
The analysis of the hematological parameters showed minimum toxic effect in mice 
treated with OMDM-2 or R-Met after 14 days of transplantation. Both OMDM-2 and 
R-Met were able to reverse the changes observed in the hematological parameters 
consequent to tumor inoculation.  
 
The hematological parameters of the tumor-bearing mice on day 14 showed 
significant changes when compared to the normal mice as shown in Table 5. The total 
WBC count was found to be doubled (P<0.01) with a reduction in the hemoglobin 
content of RBC by about 63% as compared to normal group (P<0.001). The 
differential count of WBC showed that the percentage of neutrophils increased 
(P<0.001) while that of lymphocytes decreased (P<0.05). At the same time interval, 
OMDM-2 (5 mg/kg) or R-Met (0.5 mg/kg) treatment could change these altered 
parameters to near normal as shown in Table 5. 
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Table (5): Effect of the systemic administration of OMDM-2 or R-Met on the 
hematological parameters of EAC-bearing mice 
Parameter Normal EAC tumor R-Met OMDM-2 
Hb (g/dl) 13.4±0.2 5±1.4
●●●
 10±0.3* 10±0.2* 
RBC (million/mm
3
) 8.27±0.1 3±0.3
●
 8±0.73*
 
7±0.64* 
WBC (million/mm
3
) 4.7±0.46 9±0.4
●● 
5.8±0.2* 5.5±0.7* 
Lymphocytes (%) 78.9±1.7 70±1.1
●
 71.8±2 71±1.78 
Neutrophils (%) 10.1±1.5 19±2
●●●
 12.8±1.6 12±0.6* 
Monocytes (%) 6.7±0.15 5.2±0.2 5±0.7 6.75±0.3 
 
 
Each value represents the mean ± S.E of n= 6-7 mice per data. All data were analyzed using ANOVA 
followed by Bonferroni post-hoc test for multiple comparisons of means. ●, ●●, ●●● significantly different 
from normal control at p≤ 0.05, 0.01, and 0.001, respectively.  * Significantly different from EAC 
control group at p≤ 0.05.  
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5.8 In-vitro anti-proliferative activity 
OMDM-2 was screened for its ability to reduce the cell proliferation on two different 
human cell lines, MCF-7 and U-87 cells. OMDM-2 significantly inhibited the MCF-7 
and glioma cells proliferation in a dose dependent manner after 24 hrs of incubation 
(Figure 10). The concentrations of OMDM-2 reduced the proliferation of MCF-7 and 
U-87 cells to 50% (IC50) were 4.9 µM and 2.7 µM, respectively (Figure 10).  
 
5.8.1 Role of CB-1 receptors in the OMDM-2 cytotoxicity 
The pre-treatment with NIDA 41020 (selective CB-1 antagonist) at 0.2 μM did not 
substantially change the cytotoxicity profile of OMDM-2 against MCF-7 cells 
(Figure 11). The pre-treatment with NIDA 41020 antagonised the growth inhibitory 
effects of low concentrations of OMDM-2 in U-87 glioma cells. This was not the case 
with higher concentrations (Figure 11). Noteworthy, the used concentration of NIDA 
41020 could block the CB-1 receptor without affecting the viability of both cells per 
se (data not shown). 
5.8.2 Role of TRPV1 receptors in the OMDM-2 cytotoxicity 
In U-87 glioma cells, the pre-treatment with capsazepine (selective TRPV1 
antagonist) antagonised the growth inhibitory effects of low concentrations of 
OMDM-2 (Figure 11). While in case of MCF-7 cells, capsazepine did not change the 
cytotoxicity profile of OMDM-2. Remarkably, the selected dose of capsazepine (1 
μM) reduced the viability of MCF-7 cells to a little extent (87% ± 2.3) (data not 
shown). On the other hand, it did not affect the viability of U-87 glioma cells.  
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Figure (10): Concentration response curve of OMDM-2-induced cytotoxicity. 
The effect of 24 hrs incubation with various concentrations of OMDM-2 on the proliferation of human 
breast carcinoma cells (MCF-7) [upper panel] and glioma cells (U-87) [lower panel] was determined 
fluorometrically using a Resazurin based assay. The IC50 were 4.9 µM and 2.7 µM for MCF-7 and U-
87, respectively. Each data point represents the mean ± S.E of five independent experiments.  
** Significantly different from control at p≤ 0.01. *** Significantly different from control at p≤ 0.001.  
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Figure (11): Modulatory effect of CB-1 or TRPV1 blockers pre-treatment on 
OMDM-2 induced cytotoxicity in MCF-7 and U-87 cells. 
Effect of the pretreatment with CB-1 blocker, NIDA41020, (0.2 µM) or TRPV1 blocker, capsazepine 
(1 µM) on the anti-proliferative activity of different concentrations of OMDM-2 using human breast 
carcinoma cells (MCF-7) [upper panel] and glioma cells (U-87) [lower panel]. Each data point 
represents the mean ± S.E of five independent experiments. # Significantly different from the 
individual treatment without blocker at p≤ 0.05. 
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5.9 Effect of OMDM-2 on VEGF concentration 
The concentration of VEGF, angiogenic marker, in the culture supernatants of MCF-7 
cells treated with 7.2 µM of OMDM-2 (IC50) was significantly reduced by 90% as 
compared to the MCF-7-control group (Figure 12). This experiment was conducted in 
Egypt and the IC50 was chosen according to the results of the in-vitro study carried 
out there under different culture conditions which included the addition of serum.  
 
 
Figure (12): Effect of OMDM-2 on VEGF level in MCF-7 cells. 
The VEGF concentrations in MCF-7 cells exposed to 7.2 µM of OMDM-2 for 24 hrs were evaluated 
using ELISA. Each point represents mean ± S.E of three independent experiments.  
Means were compared using paired t-test. *** Significantly different from control group at p≤ 0.001.   
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5.10 Characteristics of cell death mediated by OMDM-2 
Four different sets of experiments were used to evaluate the characteristics of cell 
death mediated by OMDM-2: 
 
5.10.1 Quantification of oligonucleosomal DNA fragments (marker of apoptotic cell 
death) 
By examining the U-87 cells after 8 hrs, 12 hrs or 24 hrs of incubation with increasing 
concentrations of OMDM-2, almost no quantitative differences in DNA fragmentation 
were observed between the control and the treated cells as shown in Figure 13. Also, 
no apoptosis was shown in MCF-7 cells exposed to increasing concentration of 
OMDM-2 for 24 hrs (Figure 13). 
 
5.10.2 Caspase-3 activity 
OMDM-2 failed to increase the activity of caspase-3 in U-87 cells at different 
concentrations and time points (Figure 14). The caspase-3 activity was not measured 
in MCF-7 cells because they lack the caspase-3 gene. 
 
5.10.3 DNA fragmentation (laddering) 
To further confirm that apoptosis is not mediating the glioma cell death, we 
performed electrophoretic analysis of DNA laddering, a key feature of cell 
undergoing apoptosis. As shown in Figure 15, cell death induced by OMDM-2 is not 
mediated by classical apoptosis or necrosis. 
 
5.10.4 Morphological changes  
As shown in Figure 16, U-87 cells treated with different concentrations of OMDM-2 
displayed marked morphological changes. The adherent cells appear round in shape, 
with extensive cytoplasmic vacuolation.  
This type of cell death fits the criteria of paraptosis which includes: rounding of the 
cells, cytoplasmic vacuolation, lack of caspase activation, and lack of apoptotic 
morphology. 
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Figure (13): Role of apoptosis in OMDM-2 mediated cytotoxicity. 
Detection of oligonucleosomes indicative of the process of apoptosis in U-87 glioma cells after 8, 12, 
and 24 hrs treatment with increasing concentrations of OMDM-2 [upper panel] and in MCF-7 cells 
after 24 hrs treatment [lower panel]. Cells were collected for apoptosis assay using cell death ELISA 
Kit. ELISA OD was normalized to protein content. Each point represents mean ± S.E of three 
independent experiments.  
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Figure (14): Caspase-3 activity 
Spectrophotometric measurement of caspase-3 activities in U-87 glioma cells exposed to increasing 
concentrations of OMDM-2 for 8, 12, and 24 hrs. 150 µg proteins were used to measure the activity of 
caspase-3. Each point represents mean ± S.E of three independent experiments.  
 
 
                                                                                             
 
 
 
 
 
 
 
 
 
Figure (15): OMDM-2 induced cell death was neither apoptosis nor necrosis.  
U-87 cells were treated for 8, 12, and 24 hours with either vehicle control (DMSO) or 20 µM 
OMDM-2. After the incubation period, the adherent and the floating cells were subjected to DNA 
extraction and qualitatively analyzed by DNA gel electrophoresis (1.5%). U-87 cells were also 
treated with 500 nM paclitaxel for 72 hours as a positive control for apoptosis or 32 mM H2O2 
(incubated for 24 hrs followed by 3 cycles of freeze-thawing) as a positive control for necrosis. 
The pattern of DNA separation for OMDM-2 treated cells appears to be different from apoptosis 
and necrosis. 
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Figure (16): Representative samples of OMDM-2 induced morphological 
changes. 
 
 
 
 
                                                                                                                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Photomicrograph observations in cultured U-87 glioblastoma cells, 20X magnification power except 
(E) and (F) 40X. Cells were treated with OMDM-2 at (A) 0 µM, (B) 0.625 µM , (C) 2.5 µM, (D) 20 
µM (E) 2.5 µM (40 X), (F) 20 µM (40 X) for 24 hrs. 
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5.11 Effect of OMDM-2 on the phosphorylation status of ERK1/2 and AKT 
To probe the involvement of ERK1/2 and AKT pathways in regulating the cell death 
mediated by OMDM-2, we assessed the effects of OMDM-2 on the level of phospho- 
ERK1/2 and AKT after 24 hrs of treatment. The U-87 cells exposed to different 
concentrations of OMDM-2 showed a tendency to increase the activity of ERK1/2 
without reaching statistical significance (Figure 17). On the other hand, the MCF-7 
cells exposed to low concentrations of OMDM-2 showed a significant increase in the 
ERK1/2 phosphorylation as compared to the control group (Figure 18). Importantly, 
the 24 hrs exposure of MCF-7 cells to a very high concentration of OMDM-2 (60 
µM) resulted in a strong decrease in the expression of ERK1/2 and consequently in its 
phosphorylated form (Figure 18).  
 
The exposure of both U-87 and MCF-7 cells to OMDM-2 did not affect the level of p-
AKT as compared to the control groups (Figures 17&18, respectively). Interestingly, 
the MCF-7 cells exposed to 60 µM of OMDM-2 showed a dramatic decrease in the 
expression of AKT protein similar to that happens with ERK1/2 (Figure 18).  
 
The U-87 and MCF-7 cells exposed to either NIDA 41020 or capsazepine, per se, did 
not show any significant changes in the expression of p-ERK1/2 and p-AKT (data not 
shown). 
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Figure (17): Effect of OMDM-2 on ERK1/2 and AKT phoshorylation in U-87 
cells.  
Control cells were cultured during the experiment in serum-free medium containing DMSO (0.5%). 
Western blot analysis was performed using antibodies recognising specific residues of pan, 
phosphorylated ERK1/2 and AKT. Pictures are representative of six independent experiments (A). 
Quantitative changes in ERK1/2 and AKT phosphorylation were determined by densitometric analysis 
of immunoblots. Data in values relative to total ERK1/2 or AKT level represent mean ± S.E of six 
independent experiments (B). 
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Figure (18): Effect of OMDM-2 on ERK1/2 and AKT phoshorylation in MCF-7 
cells.  
Control cells were cultured during the experiment in serum-free medium containing DMSO (0.5 %). 
Western blot analysis was performed using antibodies recognising specific residues of pan, 
phosphorylated ERK1/2 and AKT. Pictures are representative of six independent experiments (A). 
Quantitative changes in ERK1/2 and AKT phosphorylation were determined by densitometric analysis 
of immunoblots. Data in values relative to total ERK1/2 or AKT level represent mean ± S.E of six 
independent experiments (B). * Significantly different from control group at p≤ 0.05. 
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5.12 Optimization of OMDM-2 effect (combination therapy)  
 
5.12.1 Sensitivity of MCF-7 cells to OMDM-2 in the presence of curcumin 
The effects of 24 hrs co-exposure to different doses of curcumin on the sensitivity of 
the MCF-7 cells to OMDM-2 are shown in Table 6. Both IC50 and IC70 values were 
chosen in order to analyze the combination effect. In order to measure the increase in 
the sensitivity, a sensitization factor was determined by dividing both the IC50 and 
IC70 values for OMDM-2 alone by those in the presence of curcumin. Curcumin 
enhanced the growth inhibitory activity of OMDM-2 in a dose-dependent manner.  
 
The type of interaction between OMDM-2 and curcumin was evaluated by 
performing a series of isobologram transformations of multiple dose-response 
analyses. Representative isobolograms are presented in Figures 19, 20. These results 
indicate a strong synergistic interaction between OMDM-2 and curcumin for both 
IC70 and IC50. Using the mutually non-exclusive assumption of the CI method of 
Chou and Talalay, the CI values ranged from 0.02 to 2E
-5
 for 50-95% cell death levels 
(Figure 21). These data were consistent with the results of the isobologram analysis.  
  
5.12.2 Sensitivity of U-87 cells to OMDM-2 in the presence of curcumin 
The effects of a 24 hrs co-exposure to different doses of curcumin on the sensitivity of 
the U-87 cells to OMDM-2 are shown in Table 7. Both IC50 and IC77 values were 
chosen in order to analyze the combination effect.  
 
As shown in Figures 22, 23, the type of interaction between OMDM-2 and curcumin 
against glioma cells differ at different dose ratios. These results indicate synergistic or 
additive interaction between certain ratios of OMDM-2 and curcumin while 
antagonistic interaction with others for both IC77 and IC50. In addition, the 
combination was analyzed by the CI method as shown in Figure 24. 
 
The percentage of cells killed by drugs used in combination (fraction affected) and the 
dose reduction index (DRIs), which represent the order of magnitude (fold) of dose 
reduction obtained in combination setting compared with each drug alone, are shown 
in Table 8. 
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Table (6): Effect of curcumin on the sensitivity of MCF-7 cells to OMDM-2 
 
OMDM-2 : Curcumin  IC50 Sensitization factor IC70 
Sensitization 
factor 
OMDM-2 alone 4.9 ____ 38 ____ 
1:1 3.8 1.3 5.5 6.9 
1:2 3 1.6 4.2 9 
1:4 2.9 1.7 3.9 9.74 
1:8 1.8 2.7 2.9 13.1 
 
MCF-7 cells were incubated with serial dilutions of OMDM-2 in the absence or presence of curcumin 
for 24 hrs. IC50 and IC70 were calculated from the dose response curve. Results represent three 
independent experiments. 
 
 
 
Table (7): Effect of curcumin on the sensitivity of U-87 cells to OMDM-2 
 
OMDM-2 : Curcumin  IC50 Sensitization factor IC77 
Sensitization 
factor 
OMDM-2 alone 2.7 ____ 6.4 ____ 
1:1 3.2 0.8 5.2 1.2 
1:2 3.8 0.7 4.2 1.5 
1:8 1.9 1.4 3.5 1.8 
1:16 1 2.7 2.5 2.6 
1:32 0.3 9 1.1 5.8 
 
U-87 cells were incubated with serial dilutions of OMDM-2 in the absence or presence of curcumin for 
24 hrs. IC50 and IC77 were calculated from the dose response curve. Results represent three independent 
experiments. 
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OMDM-2 : Curcumin IC70 (µM) OMDM-2 (µM) Curcumin (µM) 
1 : 8 26.1 2.9 23.2 
1 : 4 19.5 3.9 15.6 
1 : 2 12.6 4.2 8.4 
1 : 1 11.0 5.5 5.5 
2 : 1 13.2 8.8 4.4 
4 : 1 21.3 17 4.25 
 
Figure 19: Isobol curve for the 70% inhibition of OMDM-2 / Curcumin combination against MCF-7 
proliferation; IC70 (µM) for various dose combinations. Results represent three independent 
experiments. 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
0 5 10 15 20 25 30 35 40 
C
u
rc
u
m
in
 c
o
n
ce
n
tr
a
ti
o
n
 (
µ
M
) 
OMDM-2 concentration (µM) 
IC70 
Results 
 
  P a g e | 107 
 
 
OMDM-2:Curcumin IC50 (µM) OMDM-2 (µM) Curcumin (µM) 
1 : 8 16.2 1.8 14.4 
1 : 2 9 3 6 
1 : 1 7.6 3.8 3.8 
 
Figure 20: Isobol curve for the 50% inhibition of OMDM-2 / Curcumin combination against MCF-7 
proliferation; IC50 (µM) for various dose combinations. Results represent three independent 
experiments. 
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Figure 21: Combinatory effect of OMDM-2 and curcumin in MCF-7 cells. CI/FA curve showed the 
CI vs the fraction of cells affected by OMDM-2 and curcumin in combination after 24 hrs of treatment. 
Combination analysis was done using the method described by Chou and Talalay (see materials and 
methods). Results represent three independent experiments.  
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OMDM-2 : Curcumin IC77 (µM) OMDM-2 (µM) Curcumin (µM) 
1 : 32 36.3 1.1 35.2 
1 : 4 19 3.8 15.2 
1 : 2 12.6 4.2 8.4 
1 : 1 10.4 5.2 5.2 
 
 
OMDM-2 : Curcumin IC77 (µM) OMDM-2 (µM) Curcumin (µM) 
 1 : 16 42.5 2.5 40 
1 : 8 31.5 3.5 28 
2 : 1 13.5 9 4.5 
 
Figure 22: Isobol curve for the 77% inhibition of OMDM-2 / Curcumin combination against U-87 
proliferation. (A) IC77 (µM) for the dose combinations showed synergy or additive effect. (B) IC77 
(µM) for the dose combinations showed antagonistic effect. Results represent three independent 
experiments.  
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OMDM-2 : Curcumin IC50 (µM) OMDM-2 (µM) Curcumin (µM) 
1 : 32 9.9 0.3 9.6 
 
 
 
OMDM-2 : Curcumin IC50 (µM) OMDM-2 (µM) Curcumin (µM) 
1 : 16 17 1 16 
1 : 8 17.1 1.9 15.2 
1 : 2 11.4 3.8 7.6 
1 : 1 6.4 3.2 3.2 
 
Figure 23: Isobol curve for the 50% inhibition of OMDM-2 / Curcumin combination against U-87 
proliferation. (A) IC50 (µM) for the dose combination (1:32) showed synergistic effect. (B) IC50 (µM) 
for the dose combinations showed antagonistic effect. Results represent three independent experiments.  
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Figure 24: Combinatory effect of OMDM-2 and curcumin in U-87 glioma cells. CI/FA curve 
showed the CI vs the fraction of cells affected by OMDM-2 and curcumin in combination after 24 hrs 
of treatment. Combination analysis was done using the method described by Chou and Talalay (see 
materials and methods). Results represent three independent experiments. 
 
Table (8): Fraction affected (FA) and dose reduction index (DRI) for OMDM-2 
and curcumin combination against U-87 cells 
FA  
Dose (µM) 
OMDM-2 
Dose (µM) 
Curcumin 
DRI  
OMDM-2 
DRI 
Curcumin 
0.76 15.9323 43.0063 25.4917 1.07516 
0.72 11.6286 37.0266 9.30289 1.23422 
0.71 10.7968 35.7429 4.31872 1.78714 
0.83 30.6637 58.7115 6.13275 5.87115 
0.84 34.2221 61.8577 0.85555 12.3715 
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5.12.3 Sensitivity of U-87 cells to temozolomide in the presence of OMDM-2 
The effects of 24 hrs co-exposure to different doses of OMDM-2 on the sensitivity of 
the U-87 cells to temozolomide are shown in Table 9. The sensitization factor at IC50 
level was chosen in order to analyze the combination effect. OMDM-2 enhanced the 
growth inhibitory activity of temozolomide in a dose-dependent manner.  
 
Assessment of the drug interaction was performed calculating CI. CI/fractional effect 
curves represent the CI vs. the fraction of cells affected/ killed by OMDM-2 and 
temozolomide in combination (Figure 25). This result indicates that 24 hrs exposure 
of glioma cells to OMDM-2 and temozolomide combination produced very strong 
synergism at high level of cell death (CI= 0.13 at the IC95). 
 
The percentage of cells affected by the drugs used in combination (fraction affected) 
and the fold of dose reduction obtained in combination setting compared with each 
drug alone are shown in Table 10. 
 
5.12.4 Sensitivity of the MCF-7 cells to Paclitaxel in the presence of OMDM-2 
The CI was calculated for paclitaxel and OMDM-2 combination as shown in Figure 
26. These results indicate strong synergistic activity at high levels of cell death. Also 
DRI was calculated for both drugs (Table 11).  
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Table (9): Effect of OMDM-2 on the sensitivity of U-87 cells to temozolomide 
 
OMDM-2 : temozolomide  IC50 Sensitization factor 
Temozolomide alone 709 ____ 
1:320 321 2.2 
1:160 306 2.3 
1:80 283.5 2.5 
1:40 155.8 4.5 
1:20 84 8.4 
1:10 45.1 15.7 
1:5 36 19.6 
1:2.5 38.9 18.2 
 
U-87 cells were incubated with serial dilutions of temozolomide in the absence or presence of OMDM-
2 for 24 hrs. IC50 was calculated from the dose response curve. Results represent three independent 
experiments. 
 
Table (10): Fraction affected (FA) and dose reduction index (DRI) for OMDM-2 
and temozolomide combination 
FA 
Dose (µM) 
Temozolomide 
Dose (µM) 
OMDM-2 
DRI  
Temozolomide 
DRI 
OMDM-2 
0.5 709.366 2.78763 2.50311 0.78915 
0.55 864.357 3.77598 2.79524 0.97689 
0.6 1060.55 5.14674 3.12855 1.21460 
0.65 1312.74 7.10887 3.51856 1.52433 
0.7 1648.90 10.0395 3.98929 1.94314 
0.75 2119.40 14.6815 4.58071 2.53851 
0.8 2824.93 22.6835 5.36610 3.44708 
0.85 4000.37 38.4119 6.49931 4.99257 
0.9 6350.12 77.3219 8.38274 8.16576 
0.95 13394.2 239.359 12.6442 18.0765 
0.97 22779.6 534.843 16.9396 31.8179 
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Table (11): Fraction affected (FA) and dose reduction index (DRI) for OMDM-2 
and paclitaxel combination 
FA  
Dose (µM) 
Paclitaxel 
Dose (µM) 
OMDM-2 
DRI  
Paclitaxel 
DRI 
OMDM-2 
0.17 0.013 0.55133 1.31867 0.22053 
0.52 20 10.7039 23579.6 2.14078 
0.6 250 19.1075 25043.8 1.91075 
0.68 3140 35.5274 31406.9 1.77637 
0.71 8780 45.7170 8781.62 1.14292 
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ED  ED95 ED90 ED75 ED50 
CI 0.13 0.24 0.61 1.6 
 
Figure 25: Combinatory effect of OMDM-2 and temozolomide in U-87 glioma cells. CI/FA curve 
showed the CI vs the fraction of cells affected by OMDM-2 and temozolomide in combination after 24 
hrs of treatment. Combination analysis was done using the method described by Chou and Talalay (see 
materials and methods).  Results represent three independent experiments. 
 
 
ED  ED50 ED60 ED68 ED71 
CI 0.5 0.5 0.56 0.87 
 
Figure 26: Combinatory effect of OMDM-2 and paclitaxel in MCF-7 cells. CI/FA curve showed the 
CI vs the fraction of cells affected by OMDM-2 and paclitaxel in combination after 24 hrs of treatment. 
Combination analysis was done using the method described by Chou and Talalay (see materials and 
methods). Results represent three independent experiments. 
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6. Discussion 
Cannabinoid-based therapies are increasingly introduced into the palliative care of cancer 
(Pertwee, 2009). Δ9-THC (dronabinol) and LY109514 (nabilone) are approved to be used as 
valuable adjunctive agents to treat nausea and vomiting, weight loss and lack of appetite 
associated with cancer chemotherapy (Pertwee, 2009).  
But also cannabinoids themselves showed potential antitumor activity. They are reported to 
influence cancer cell growth and apoptosis (Guzmán et al., 2002) and suppress tumor 
neovascularization and metastasis (Blázquez et al., 2003). However, their clinical usage is 
severely restricted by their psychotropic nature. Thus novel approaches are required to 
benefit from the potential anticancer activity of cannaboinid based drugs. The rationale 
behind this study was provided by a simple consideration based on previous reports: if 
endocannabinoid concentrations are enhanced in some tumors
 
(Schmid et al., 2002)
 
and 
thereby exert a tonic inhibition of cancer cell proliferation (Ligresti et al., 2003), then 
substances that inhibit the reuptake of endocannaboids like OMDM-2 (Di Marzo et al., 2008) 
should be capable of inhibiting cancer growth. This assumption, if valid, would open the way 
to develop new cannabinoid related anti-cancer drugs that are potentially devoid of, or at least 
very low in, the psychotropic (Guzmán, 2003) or immunosuppressive (Bifulco et al 2004) 
side effects typical for direct agonists of cannabinoid receptors. Their site of action would be 
restricted to an ongoing metabolism of endocannbinoids i.e. at the site of cancer growth and 
thus more selective. Therefore, we investigated the in-vivo and in-vitro antitumor potential of 
OMDM-2. We further were interested in investigating the possible mechanism(s) of action 
involved in this activity.  
We selected the solid Ehrlich tumor as an undifferentiated solid tumor derived from mouse 
breast adenocarcinoma which is an aggressive, virulent and rapidly growing tumor denoting 
high grade of malignancy (Nascimento et al., 2006; Silva et al., 2006; Sakai et al., 2010).  
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Utilizing this transplantable model of tumor has the advantage that there is a previous 
knowledge of the amount to be inoculated and the sites of injections to obtain different forms 
of cancer (liquid or solid) (Kabel et al., 2013). Also, rapid development of the tumor leads to 
a short study duration (Stewart, 1959). Ehrlich carcinoma resembles human tumors which are 
most sensitive to chemotherapy due to the fact that it is undifferentiated and has a rapid 
growth rate (Ozaslan et al., 2011; Kabel et al., 2013). It is commonly used as a tumor model 
to investigate the antitumor effects of new drugs (Silva et al., 2006; Sakai et al., 2010; Kabel 
et al., 2013).  
Initial and basic criteria for judging the value of any new anticancer drug is the reduction of 
solid tumor volume, the prolongation of life span of tumor bearing animals, and the 
decrement of the elevated levels of WBC in their blood samples (Oberling and Guerin, 
1954; Marklund et al., 1982). 
Antitumor activity 
The current study showed that the stable anandamide analog, R-Met (0.5 mg/kg, i.p.), an 
agonist for the CB-1 receptor (Ki 20 nM) and to a lower extent also an agonist for the 
TRPV1, administered every third day for 6 doses to EAC-bearing mice significantly reduced 
the tumor volume and impeded the tumor weight. These findings are in accordance with 
previous studies showing that anandamide was able to decrease the proliferation of breast 
cancer cells in-vitro by decreasing the levels of the long form of the prolactin receptor (De 
Petrocellis et al., 1998) and inhibited the nerve growth factor (NGF)-mediated proliferation 
by decreasing the expression of the Trk NGF receptor (Melck et al., 2000). Also, Eichele et 
al (2009) reported that R-Met, potently and selectively, inhibited the proliferation of human 
cervical carcinoma cells.  
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In the present study, the antitumor activity of R-Met was counteracted by a pre-treatment 
with the CB-1 blocker, NIDA 41020, thus suggesting that CB-1 receptors are uniquely 
involved in the in-vivo antitumor effect of this compound. This is augmented by Bifulco et al 
(2004) who reported that the CB-1 receptor antagonist SR141716A (0.2 μM) counteracted 
significantly the in-vitro effects of Met-F-AEA. In addition to other in-vitro
 
(Khanolkar et 
al., 1996) and in-vivo reports
 
(Burkey and Nation, 1997) which demonstrate that R-Met is 
more potent and selective for the CB-1 receptor than anandamide. Thus its anticancer 
mechanisms appear to be uniquely related to the CB-1 mediated pathways
 
(Sarfaraz et al., 
2008). 
 
The endocannabinoid reuptake inhibitor, OMDM-2 is an inhibitor of the putative 
endocannabinoids membrane transporter and as such it inhibits their cellular reuptake (Ortar 
et al., 2003). This mode of action will potentiate the effect of extracellular AEA on the CB 
receptors (Ortar et al., 2003). Increasing the endocannabinoid tone by using OMDM-2 
showed promising results in different models of diseases such as anorexia (Lewis and Brett, 
2010), multiple sclerosis (Mestre et al., 2005), pain (De Lago et al., 2004), and sleep 
disorders (Murillo-Rodríguez et al., 2013).  
Our study showed here for the first time that the systemic administration of OMDM-2 (5 
mg/kg, i.p.) every third day for 6 doses was able to strongly and significantly reduce the 
tumor volume developed in the right flank of mice using s.c EAC cells. At the end of the 
experiment, the average size of the tumors treated with OMDM-2 was ~ 62% of those treated 
with the vehicle. The antitumor activity of OMDM-2 was further confirmed in our study by 
its ability to regress tumor weights developed in mice at all time points as efficaciously as the 
reference standard carboplatin. Especially at the early stage of the tumor development 
OMDM-2 reduced tumor weight by ~ 88%. These data indicate that endocannabinoids act as 
endogenous tumor suppressors and their administration would be more valuable at the first 
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stages of cancer development as reported by Pisanti and Bifulco (2009). Our results also 
support the finding that endocannabinoids can tonically control tumor cell proliferation in-
vivo as shown by Bifulco et al (2004) who decreased the thyroid tumor volume in athymic 
mice by intratumoral administration of endocannabinoid degradation inhibitors. Our data 
indicate for the first time that the antitumor activity of the endocannabinoid reuptake 
inhibitors can be achieved by a systemic administration and is not limited to their local 
administration at the site of tumor growth (Bifulco et al., 2004). An approach which makes 
the shift to the clinical trials easier by avoiding the intratumoral administration as already 
done by Guzmán et al (2006) who administered the Δ9-THC intrcranially to nine patients 
with recurrent glioblastoma multiforme.   
We showed here also that the in-vivo antitumor effect of OMDM-2 in EAC bearing mice was 
not mediated by the CB-1 receptor. These data are in contrast to that obtained by Bifulco et al 
(2004) who reported that the antitumor activity of the transporter inhibitor VDM-11 which 
has a pharmacodynamic profile similar to OMDM-2, was mediated by the CB-1 receptor. 
This discrepancy suggests that other mechanisms might be also involved, possibly related to 
the pharmacokinetics and to the higher metabolic stability of OMDM-2 in-vitro
 
(Ortar et al., 
2003) and in-vivo (De Lago et al., 2004) as compared to VDM-11. Also, the discrepancy may 
be related to the difference in the type of cancer used in Bifulco et al (2004) study (thyroid 
cancer). It is well known that the receptors involved in mediating the antitumoral action of 
endocannabinoids differ according to the type of cancer (Pisanti and Bifulco, 2009).  
 
Increased life span is a parameter that reflects the efficacy of anti-neoplastic agents. The 
systemic administration of OMDM-2 or R-Met was able to extend the life span of tumor 
bearing mice. In our study the effect of OMDM-2 on increasing the life span was, like the 
antitumor activity, not affected by blocking the CB-1 receptor. These results clearly 
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augmented the antitumor effect of OMDM-2 on EAC tumor cells and further support that its 
effect was not mediated by the CB-1 receptor.   
 
In-vitro anti-proliferative activity 
We next investigated the mechanism(s) of action of OMDM-2 by studying its anti-
proliferative effect in-vitro on the human breast (MCF-7) and brain (U-87) cancer cell lines. 
OMDM-2 dose dependently inhibited the proliferation of both cell lines. The concentrations 
of OMDM-2 producing effects on cell proliferation in our study are in the range generally 
used for uptake inhibition experiments. The IC50 for OMDM-2 (for uptake inhibition) ranged 
from 3-17 µM depending upon cell type and experimental design (Ortar et al., 2003; De 
Lago et al., 2006). These findings augment a previous in-vitro study which showed that 
OMDM-2 produces a rapid loss of rat C6 glioma cell viability if used over the same 
concentration range required for the inhibition of the AEA uptake in-vitro
 
(De Lago et al., 
2006). Our results showed a significant decrease in U-87 glioma cells proliferation at the 
lowest concentrations of OMDM2 (lower than used for reuptake inhibition) similar to the 
results obtained by De Lago et al (2006).  
Interestingly, our in-vivo results were supported by in-vitro data which showed that the anti-
proliferative effect of OMDM-2 was not mediated by the CB-1 receptor expressed on MCF-7 
human breast cancer (Di Marzo et al, 2001). This indicates that the CB-1 receptors are not 
likely to be involved in mediating the anticancer activity of OMDM-2 against both human 
and murine breast cancer.  
The finding of inhibitory effects on cancer cell proliferation by the combination of OMDM-2 
with the CB-1 receptor antagonist suggests that endocannabinoids might exert their tonic 
anti-proliferative effects also through non-CB-1 receptor-mediated mechanisms, particularly 
when CB-1 receptors are blocked. These mechanisms are not likely to involve the CB-2 
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receptors, because these receptors were previously shown not to be involved in the 
endocannabinoid anti-proliferative effects against colorectal (Ligresti et al., 2003) and 
thyroid (Bifulco et al., 2004) cancers.  
Looking at the TRBV1, there is contradictory evidence on the involvement of TRBV1 in the 
action of reuptake inhibitors. Some studies showed that the reduction of intracellular AEA by 
reuptake inhibitors will reduce the effectiveness of accumulated AEA at the TRPV1 given 
that the binding site for AEA on these receptors is intracellular
 
(De Petrocellis et al., 2001). 
However, other studies showed that the reuptake inhibitors may act by blocking the transport-
mediated release of intracellular AEA from TRPV1-expressing cells (Cabranes et al., 2005), 
thereby potentiating AEA action at intracellular binding site on TRPV1 receptors.  
We investigated the involvement of TRPV1 in OMDM-2 activity by using the TRPV1 
blocker, capsazepine. Our results indicated that the TRPV1 receptors ,expressed on MCF-7 
breast cancer cells (Barbero et al, 2006), are not responsible for mediating the anti-
proliferative effect of OMDM-2.  
Taken our in-vitro and in-vivo data together the findings indicate that the antitumor activity of 
OMDM-2 against breast cancer is independent on both cannabinoid (CB-1) and vanilloid 
(TRPV1) receptors. Several other membrane proteins and ion channels are being proposed as 
molecular targets for endocannabinoid under both physiological and pathological conditions
 
(Di Marzo et al., 2002). The exact mechanism underlying the anti-cancer effect of OMDM-2 
will clearly require further investigations.  
Our results in glioma cells showed that the CB-1 and TPRV1 receptors (Contassot et al., 
2004) mediated, at least in part, the anti-proliferative activity of low concentrations of 
OMDM-2 (≤ 5µM) while these were not the case with higher concentrations (≥ 10 µM). 
These results are in line with De Lago et al (2006) who showed that both receptors were not 
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involved in mediating the death of rat glioma cells using 10 µM of OMDM-2. These findings 
indicate that the low concentrations of OMDM-2 may mediate their activity through the 
effect of accumulated endocannabinoids on CB-1 and TRPV1 receptors. The CB-1 and 
TRPV1 independent effects of high concentrations of OMDM-2 could be attributed to a 
direct effect. Although described as an anandamide analogue and active as an anandamide 
reuptake inhibitor, OMDM-2 is structurally more similar to oleylethanolamide (Lewis and 
Brett, 2010) which acts as an agonist at the nuclear PPAR-α receptor (Fu et al., 2003). The 
activation of PPARα receptors could be useful for the prevention or the treatment of different 
cancers (Peters et al., 2012). Different PPARα agonists inhibited the growth of tumors that 
were derived from melanoma, Lewis lung carcinoma, glioblastoma and fibrosarcoma cell 
lines (Peters et al., 2012). There is little published information as yet on the pharmacological 
actions of OMDM-2 considering this aspect. 
Hematological parameters 
Pal et al (1993) reported that the growth of EAC in Swiss mice was accompanied by a 
decrease in the hemoglobin and the RBC values. Similar results were observed in the present 
study in the animals of the EAC tumor control group. The decrease in hemoglobin is a 
consequence of the reduction of RBC or a reduction in the hemoglobin production or both. 
This may occur either due to iron deficiency or to hemolytic or other myelopathic conditions 
(Hoagland, 1982). 
The systemic administration of OMDM-2 was able to significantly increase the erythrocyte 
count and the hemoglobin level when compared to those of EAC control mice. These effects 
can be owed to the ability of accumulated AEA to promote the growth of hematopoietic cell 
as shown by Valk et al (1997). In addition, OMDM-2 was able to reduce the elevated level of 
WBC in EAC mice near to the normal level. These indicating parameters revealed that the 
systemic administration of OMDM-2 could restore the hematological profile of tumor 
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bearing mice nearly to the normal levels. An effect which may be particularly attractive if 
endocannabinoids-enhancing strategies were to be included in poly-chemotherapeutic 
protocols. 
 
Role of TGF-β1/CD-105 system 
TGF-β1 behaves as a tumor suppressor at early stages of tumor development but promotes 
tumor progression at later stages (Pérez-Gómez et al., 2010) by promoting tumor cell 
migration, invasion and metastasis in a cell-autonomous manner, and by influencing the 
tumor microenvironment facilitating angiogenesis and evasion of the immune system 
(Derynck et al., 2001; Massagué, 2008). Most studies about the involvement of endoglin 
(TGF-β1 receptor) in cancer have focused on its role as a pro-angiogenic molecule and its 
usefulness as a marker of microvessel density (MVD) in tumors. However, there is evidence 
that endoglin modulates cell proliferation, adhesion and migration of neoplastic cells 
suggesting a direct involvement of endoglin in cancer either by modulating the response of 
tumor cells to TGF-β or by as yet not completely understood TGF-β independent mechanisms 
(Pérez-Gómez et al., 2010). 
To our knowledge, the time course expression of TGF-β1 has not been previously evaluated 
in the EAC model, the untreated EAC-group showed higher serum concentrations of TGF-β1 
compared to the normal group on days 7, 14, and 21. We hypothesize that the high levels of 
TGF-β1 may represent a compensatory response in order to suppress the initiation or 
expansion of a tumor but these higher concentrations, especially at an early stage of tumor 
development, were not able to suppress neither the tumor growth nor the angiogenesis. Our 
finding of a high intra-tumoral expression of CD-105 receptors in the EAC group on day 7 
(early stage) support this hypothesis since high concentrations of CD-105 modulate the TGF-
β1 signaling and eventually lead to the loss of the growth inhibitory action of TGF-β1 
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(Warrington et al., 2005). This could insulate tumor and endothelial cells from the negative 
control effects of TGF-β1 and thus contribute to tumor growth and angiogenesis
 
(Duff et al., 
2003).  
 
High levels of TGF-β1 mediate autocrine production of other growth promoting factors 
suggesting an indirect mitogenic effect of TGF-β on the cell proliferation (Kay et al., 1998). 
The high serum concentrations of TGF-β1 and the low expression of CD-105 combined with 
the high angiogenesis (%) and tumor weights as seen in our study in the EAC-group at days 
14 and 21 support such a role for TGF-β1. It further supports that the tumor growth during 
these late stages may be indirectly dependent on TGF-β1/CD-105 as described by Nimeh et al 
(2001) who proposed that TGF-β1 may be an indirect but necessary player in tumor 
angiogenesis and growth in-vivo.  
 
In our study, the systemic administration of either OMDM-2 or R-Met resulted in a 
significant increase in the TGF-β1 concentrations at an early stage of tumor development (day 
7) paralleled by the down regulation of the expression of CD-105. In such a scenario high 
levels of TGF-β1 can execute their tumor suppressing activity and inhibit tumor growth as 
shown in our study. Furthermore, the tumor expression levels of endocannabinoids can 
modulate the value of endoglin-positive vascular density as a prognostic marker as shown 
recently  in prostate cancer patients (Fowler et al., 2013). 
 
Interestingly the reference standard carboplatin did not affect the levels of TGF-β1 but 
showed a significant anti-endoglin activity as shown recently by Ziebarth et al (2013).   
 
The ability of OMDM-2 to continue its tumor suppressing activity at days 14 and 21 may be 
ascribed to the ability of accumulated AEA to inhibit other growth factors essential for tumor 
growth such as EGF (Guindon and Hohmann, 2011). On the other hand, the loss of the 
antitumor potential of R-Met on day 14 may be explained as a pharmakodynamic tolerance 
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with desensitization and down regulation of CB-1 as also recently shown by Falenski et al 
(2010).  
 
With respect to the EAC model, our data showed a tendency for a negative correlation 
between serum TGF-β1 levels and tumor weights in this model at early stage of tumor 
development. The presence of such a correlation is supported by Yamaguchi et al (1997) 
who showed a significant negative correlation between TGF-β1 concentrations and the tumor 
size (r = -0.327, p < 0.03) in hepatocellular carcinoma. 
Angiostatic activity 
Considering that angiogenesis is essential for tumor growth, we investigated whether the 
antitumor effect of OMDM-2 may be correlated to its anti-angiogenic activity. The Evans 
Blue dye extravasation technique was used to measure the permeability of albumin for the 
capillaries in the tumor tissue as a reliable measure of angiogenesis (St-Pierre et al., 2006). 
This technique is based on the principle that all forms of pathological angiogenesis including 
neovascularization induced by tumors are characterized by vascular hyperpermeability 
(Dvorak, 2002). Evans Blue dye avidly binds to intravascular albumin, and is thus a reliable 
way to assess transvascular fluxes of macromolecules (Roghani et al., 2011).  
 
Our study showed that the systemic administration of OMDM-2 significantly reduced the 
tumor vascular permeability. This also suggests that increasing the endocannabinoid tone by 
inhibiting their catabolism could be used as a tool to inhibit angiogenesis. This hypothesis is 
further supported by De Filippis et al (2010) who showed that the local administration of 
AA-5-HT, a FAAH inhibitor, significantly and dose-dependently reduced the new vessel 
formation in chronic granulomatous inflammation in rats.  
The significant anti-angiogenic activity of R-Met seen in our study indicates that its tumor 
reducing ability may be in part mediated by anti-angiogenesis in accordance with Pisanti et 
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al (2007) who demonstrated the anti-angiogenic activity of AEA in-vitro and in-vivo thereby 
supporting its tumor suppressing action. 
 
Our finding that the anti-angiogenic effect of R-Met was mediated by CB-1 corresponds to 
previous reports showing that the activation of CB-1 by anandamide inhibited angiogenesis 
and thereby retarded skin cancer and glioma growth in-vivo (Pisanti et al., 2007). In our 
study the anti-angiogenic activity of OMDM-2 was, like the antitumor activity, not mediated 
by CB-1. Importantly, the CB-1 antagonist (NIDA 41020) also exerted a significant, albeit 
small, anti-angiogenic action per se. This supports earlier report that pharmacological and 
genetic inactivations of CB-1 inhibit angiogenesis (Pisanti et al., 2011).  
 
The anti-angiogenic activity of NIDA 41020 may be explained by the ability of CB-1 
antagonism to inhibit the proliferation, migration and differentiation of endothelial cells in 
response to angiogenic growth factors like basic fibroblast growth factor (bFGF) (Pisanti et 
al., 2011). Further, it should be considered that the presently available CB-1 antagonists, 
including NIDA 41020, act not only as antagonists but also as inverse agonists (Pisanti et al., 
2011). They block the basal constitutive activity of CB-1 and thereby the transduction 
pathways downstream the tyrosine-kinase receptors (RTK) coupled to the CB-1 receptor 
including the ERK-MAPK cascade (Bouaboula et al., 1997). It is well known that 
angiogenic factors like bFGF stimulate their respective tyrosine-kinase receptors thereby 
inducing ERK-MAPK and Akt signaling pathways (Cross et al., 2001). Therefore inverse 
agonism could be a mechanism by which NIDA 41020 could switch off ERK and Akt 
activated by angiogenic factors as a consequence of a negative interference with particular 
RTK pathways. Regarding the anti-angiogenic activity of carboplatin, we hypothesize that 
this effect was indirectly obtained by decreasing the tumor size which in turn decreases the 
required blood supply. 
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We next sought to determine the mechanism by which OMDM-2 prevents vascular 
permeability. We evaluated the level of VEGF, also known as vascular permeability factor, 
because it is the most potent angiogenic and micro vascular permeability factor identified so 
far (Sheng et al., 2004). Our data showed that the level of VEGF was significantly reduced in 
MCF-7 cells exposed to OMDM-2. This is supported by a study with the prostate cancer cells 
LNCaP in which the cannabinoid receptor ligand WIN55,212-2 decreased the expression 
level of VEGF by 47% (Sarfaraz et al., 2007). These findings indicate that increasing the 
endocannabinoid tone in the tumor cells would result in a decreased secretion of the VEGF 
and hence its consequent angiogenesis and metastasis.  
 
Type of cell death 
Cell death has been classified into two main types: programmed cell death (PCD) and passive 
(necrotic) cell death. PCD is morphologically classified into three main types (Sperandio et 
al., 2004), including apoptosis, autophagy and non-lysosomal vacuolated degeneration, the 
latter of which includes oncosis and paraptosis. Previous reports indicated that endogenous 
cannabinoids inhibit the cell proliferation without inducing apoptosis as shown with human 
colon cancer cells (Linsalata et al., 2010) and cholangiocarcinoma (Demorrow et al., 2008). 
Also, AEA was able to induce non-apoptotic cell death in human breast cancer and rat 
thyroid epithelial cancer cell lines via a modulation of expression and activity of key S phase 
regulatory proteins (De Petrocellis et al., 1998; Bifulco et al., 2001; Laezza et al., 2006). 
However, AEA has also been described as being an apoptosis inducer in many cell types like 
colorectal cancer, gastric cancer, osteosarcoma, glioma or prostate cancer cell lines 
(Contassot et al., 2004; Hsu et al., 2007; Miyato et al., 2009; Patsos et al., 2010).  
In the present study OMDM-2 did neither induce a coordinated internucleosomal degradation 
of DNA nor could the typical DNA-laddering be detected. Furthermore, we found that the 
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OMDM-2 mediated cell death was caspase-3 independent as OMDM-2 failed to increase the 
activity of caspase-3 in human glioma cells at all time points. The non-involvement of 
caspase-3 was further supported by the ability of OMDM-2 to induce cell death in MCF-7 
strain used in our study which lacks the caspase-3 gene (Jänicke et al., 1998; Dumont et al., 
2007; Ubol et al., 2007). Other strains of MCF-7 cells showed an expression for the caspase-
3 gene and their deaths were mediated by its activation (Yang et al., 2006).    
Collectively, these results suggest that the classical necrosis and the caspase driven apoptosis 
were not the major contributors to the cell death mediated by endogenous cannabinoids in our 
study. Our results are in line with previous reports using different cell lines, neuroblastoma 
(Hamtiaux et al., 2011) and colorectal carcinoma (Patsos et al., 2005). Interestingly, an 
unusual form of cell death has also been reported by Mimeault et al (2003) in response to 
anandamide in prostate carcinoma cells but was simply described as apoptotic/necrotic cell 
death. In a more recent study, using also anandamide, caspase-3 activation was found to be 
unnecessary to mediate the non-apoptotic and non-necrotic cell death in colorectal carcinoma 
(Patsos et al., 2010).  
Induction of cell death other than apoptosis could be particularly beneficial for those tumor 
cells that have become resistant to the induction of apoptosis, and currently there is growing 
interest in the field of non-apoptotic forms of cell death (Tsujimoto, 2012).     
Moreover, the microscopic images of U-87 cells treated with OMDM-2 for 24 hrs 
demonstrated gross morphological changes in support of a paraptosis like cell death. 
Paraptosis is a new type of PCD on which there are only a few reports until now, 
characterized by rounding of the cells, cytoplasmic vacuolation derived from endoplasmic 
reticulum and/or mitochondria swelling; it is caspase independent and lacks both DNA 
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fragmentation and the apoptosis morphological changes (Sperandio et al., 2004; Zhang et 
al., 2009).  
A recent study showed that increasing the cannabinoid tone decreased the lymphoma cell 
viability in a caspase-3 independent manner (Wasik et al., 2011). Moreover, the cells 
responded to cannabinoid treatment through the formation of cytoplasmic vacuoles. The 
authors hypothesize that the observed features resemble paraptosis-like cell death, not 
previously described in response to cannabinoids (Wasik et al., 2011).  
 
Based on our data we hypothesize that the OMDM-2 mediated cell death in glioma cells may 
also be paraptosis. This interpretation is supported by our findings that OMDM-2 treatment 
for 24 hrs did not affect the phosphorylated levels of both ERK1/2 and AKT proteins. Our 
findings further agree with other reports showing that MAPK and AKT pathways are not 
involved in mediating parapoptosis (Asare et al., 2008; Sun et al., 2010). Here the OMDM-
2-induced paraptosis was different from the insulin-like growth factor I receptor (IGFIR)-
induced paraptosis which requires the participation of the MAPK/ERK and JNK signalings 
(Sperandio et al., 2004; Asare et al., 2008). 
Our data and previous findings indeed demand further investigations to characterize the 
molecular mechanisms mediate this rather new process of paraptosis. In addition to confirm 
that the paraptosis may be one of the possible types of cell death induced by endogenous 
cannabinoids.  
 
Interestingly, our study showed that the exposure of MCF-7 to OMDM-2 for 24 hrs resulted 
in a significant increase in the phosphorylation of ERK1/2 which was not paralleled by any 
effect on the AKT signaling. The accumulated AEA may be responsible for the activity of 
ERK1/2 and hence the anti-proliferative activity. This interpretation is based on previous 
reports showing that AEA leads to an anti-proliferative activity in MCF-7 by inhibiting 
adenylyl cyclase and thus activating the Raf-1/ERK/MAPK cascade, which, upon sustained 
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activation, ultimately down-regulates prolactin and nerve growth factor Trk receptors (De 
Petrocellis et al., 1998; Melck et al., 2000; Caffarel et al., 2012). Collectively, these data 
indicate that the mechanism of action of endogenous canabinoids differ according to the type 
of cancer. Further investigations are required to investigate the type of cell death induced by 
OMDM-2 in MCF-7 cells. 
 
Drug combination 
In cancer therapy, the employment of combinations of drugs rather than a single drug 
represents a therapeutic strategy with distinct advantages. On one hand, the contemporaneous 
activation of different biochemical pathways can achieve synergistic effects; on the other 
hand, the combination can result in a reduction of the dose of each single drug thereby 
reducing side effects (Calvaruso et al., 2012). 
Recent studies have demonstrated the ability of endo/cannabinoids to synergize with other 
molecules to trigger death pathways in cancer cells. In particular, Calvaruso et al (2012) 
demonstrated that the synthetic cannabinoid WIN55,212-2 sensitizes hepatocellular 
carcinoma cells to apoptosis, mediated by tumor necrosis-related apoptosis inducing ligand 
(TRAIL). Also, in pancreatic cancer cells the combination of cannabinoids with gemcitabine, 
a pyrimidine analog largely employed in anticancer therapy, induces synergistic effects via 
the activation of autophagy (Donadelli et al., 2011). Another example of synergistic effects 
of cannabinoids with other drugs has been reported by Gustafsson et al (2009) who 
demonstrated that the synthetic cannabinoid HU210, anandamide and its other derivatives 
induce synergistic effects when employed in combination with the classic pyrimidine 
antagonist 5-fluorouracil (5-FU) in the colorectal carcinoma cells.  
Our combination studies investigated two different aspects. First we combined OMDM-2 
with a natural anticancer drug with the question whether we could reduce the dose of 
OMDM-2. Second we combined OMDM-2 with benchmark chemotherapeutics to investigate 
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whether we could increase the sensitivity of the cancer cells to these drugs as well as to 
decrease their dose related side effects by the addition of OMDM-2.   
 
In our study, co-incubation of MCF-7 cells with curcumin and OMDM-2 showed that 14.4 
µM and 23.2 µM of curcumin sensitized MCF-7 cells to OMDM-2 by approximately 3-fold 
at the IC50 level and 13-fold at IC70 level, respectively. The isobologram technique showed 
that the two agents given concurrently demonstrate strong synergistic activity. Synergism was 
also assessed using the CI method which takes into account the potency of each drug alone, 
the potency of drug combination, the shape of their dose-effect curves and it quantitates the 
synergism or antagonism at different concentrations and at different effect levels. Exposure 
of MCF-7 cells to different ratios of OMDM-2 plus curcumin resulted in a consistent 
synergistic effect (CIs were less than 1 over all the range of cytotoxicity examined). 
 
In our study MCF-7 cells showed a high resistance to paclitaxel. The deficiency of caspase-3 
gene in MCF-7 cell line used in our study contributes to its chemotherapeutic resistance as 
shown by (Yang et al., 2001; Ubol et al., 2007; Yang et al., 2007). Furthermore, it is well 
known that paclitaxel mediates its anticancer activity in a caspase-3 dependent manner 
(Mollinedo and Gajate, 2003; Impens et al., 2008; McGrogan et al., 2008; Rensen et al., 
2009). On the other hand, the addition of OMDM-2 increased significantly the sensitivity of 
MCF-7 cells to paclitaxel and induced a potent synergistic effect. 
 
Glioblastoma multiforme (GBM) exhibits a high resistance to standard chemotherapy and 
radiotherapy (Franceschi et al., 2009). Current strategies for the treatment of GBM are only 
palliative and large numbers of chemotherapeutic agents [e.g., alkylating agents such as 
temozolomide and nitrosureas such as carmustine] have also been tested, but they display 
limited efficacy (Nieder et al., 2006; Wong et al., 2007). It is therefore essential to develop 
new therapeutic strategies for the management of GBM. Nowadays, it is believed that the 
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development of new combinational therapies may contribute to enhance the survival of 
patients suffering from GBM (Torres et al.,2011). 
Our combination studies showed indeed promising results, the co-incubation of U-87 glioma 
cells with curcumin and OMDM-2 showed that 9.6 µM and 35.2 µM of curcumin sensitized 
U-87 cells to OMDM-2 by approximately 9-fold at the IC50 level and 6-fold at IC77 level, 
respectively. Our results also indicated that the previous combination could be synergistic 
depending on the ratio and the concentrations of the drugs. Importantly, our study showed 
that OMDM-2 was able to sensitize the glioma cells to temozolomide and to potentiate its 
cytotoxic ability. Interaction assessment using the combination index method revealed that 
the drug interaction was synergistic. Also we found that OMDM-2 was able to significantly 
reduce the dose of temozolomide required to achieve the IC50 against U-87 cells. These 
findings support the hypothesis of Torres et al (2011) that temozolomide/cannabinoid could 
be of potential clinical interest for the management of glioblastoma.  
Additionally, GW Pharmaceuticals has recently announced that it has commenced a Phase 
1b/2a clinical trial for the treatment of recurrent GBM. In this study 20 patients will 
participate and its objective is to assess the tolerability, safety and pharmacodynamics of a 
mixture of two principal cannabinoids, THC and cannabidiol (CBD) in a 1:1 allocation ratio, 
in combination with temozolomide in patients with recurrent GBM. Secondary endpoints 
include additional pharmacokinetic and biomarker analyses and additional measurable 
outcomes of tumor response.  
 
In conclusion, this study indicates that modulating the endogenous levels of cannabinoids 
could be a promising strategy to benefit from the potential anticancer activity of direct 
cannabinoids, in particular the combination therapies with natural or benchmark 
chemotherapeutics.   
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7. Summary and conclusion 
Summary  
Direct cannabinoid agonists suppress the growth of cancer cells in several preclinical studies. 
However, their clinical application is hampered by the receptor mediated side effects.  In order 
to avoid these side effects; we chose an indirect approach by using OMDM-2, a selective 
inhibitor of the cellular re-uptake of endocannabinoids. We investigated the antitumor activity 
and the possible mechanism(s) of action of OMDM-2 by using both in-vivo (Murine model of 
breast cancer) and in-vitro (Human glioma and breast cancer) studies. Furthermore, we 
evaluated the possibility of combining the endocannabinoid based drug, OMDM-2, with 
natural or benchmark chemotherapeutic agents. This would enhance its potential applicability 
in cancer therapy. 
The main findings of the present work were as follows: 
1- Anti-tumor potential of OMDM-2 
 The systemic administration of OMDM-2 to EAC-bearing mice resulted in a 
significant antitumor activity comparable to the direct cannabinoid agonist, R-
Met. 
 OMDM-2 was able to increase the life span of the tumor bearing mice as 
compared to the tumor control group. 
 The anti-proliferative activity of OMDM-2 was not specific to certain species 
or type of cancer as it inhibited the growth of both human and murine breast 
cancers and of human U-87 glioma cells.  
 The systemic administration of OMDM-2 was able to restore the 
hematological profile of EAC bearing mice nearly to the normal levels. 
 
2- Mechanisms of action 
 Involvement of CB-1 receptor 
Breast cancer: Both in-vivo and in-vitro studies indicated that the effect of 
OMDM-2 was not mediated by the CB-1 receptor. 
 
Glioma: Our in-vitro studies indicated that the effects of low concentrations of 
OMDM-2 were mediated, at least in part, by the CB-1 receptor while these were 
not the case with high concentrations. 
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 Involvement of TRPV1 receptor 
Breast cancer: Both in-vivo and in-vitro studies indicated that the effect of 
OMDM-2 was not mediated by the TRPV1 receptor. 
 
Glioma: Our in-vitro studies indicated that the effects of low concentrations of 
OMDM-2 were mediated, at least in part, by the TRPV1 receptor while these were 
not the case with high concentrations. 
 
 Anti-angiogenic activity 
OMDM-2 showed a significant anti-angiogenic activity using the Evans Blue 
method and this effect was, at least in part, mediated by decreasing the level of 
VEGF. 
 
 TGF-β1/CD-105 system 
This system appears to be involved in mediating the antitumor potential of 
OMDM-2 especially at early stages of tumor development by increasing the level 
of TGF-β1 paralleled with down-regulating the expression of CD-105. 
 
 Caspase-3 involvement 
Cell death mediated by OMDM-2 seems to be caspase-3 independent.  
 
 Morphology of cells 
U-87 cells treated with different concentrations of OMDM-2 displayed marked 
morphological changes. The adherent cells appear round in shape, with extensive 
cytoplasmic vacuolation. 
 
 Type of cell death 
Based on four different experimental set ups, it seems that the classical necrosis 
and caspase-3 dependent apoptosis are not the major contributors to the OMDM-2 
mediated cell death. We suggest that paraptosis may be involved in glioma cell 
death. 
 
 Activity of ERK1/2 and AKT signalings 
OMDM-2 showed an increase in the activity of ERK1/2 signaling in MCF-7 cells 
but did not have any effect on p-ERK1/2 in U-87 cells. The activity of AKT 
signaling was not affected by OMDM-2 in both cell lines. 
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3- Optimization of OMDM-2 treatment (combination studies)  
The isobole, DRI and combination index methods were used to demonstrate whether 
there are synergistic, additive or antagonistic effects between OMDM-2 and curumin 
in both MCF-7 and U-87 glioma cells. The same analyses were used to evaluate the 
combination between OMDM-2 and Paclitaxel in MCF-7 cells as well as between 
OMDM-2 and temozolomide in U-87 glioma cells. The addition of curcumin to MCF-
7 or glioma cells increased their sensitivity to OMDM-2 and induced potent 
synergistic effects. Also, our combination studies indicated that the addition of 
OMDM-2 to the chemotherapeutic resistant breast and glioma cancer cells not only 
increased their sensitivity but also decreased the required dose of benchmark 
chemotherapeutics.  
 
Conclusion 
This is the first report that the systemic administration of endocannabinoid reuptake inhibitor, 
OMDM-2, can impede the tumor growth and angiogenesis in-vivo indicating that the 
antitumor activity of this class of drugs is not limited to their local administration at the site of 
tumor growth. This makes the shift to clinical trials easier by the administration of the drugs 
systemically rather than intratumorally. Regardless the mechanism of the anticancer activity 
of endocannabinoids, our data suggest that a new and possibly safer strategy to block the 
tumor growth and angiogenesis could arise from substances that selectively delay 
endocannabinoid degradation. These compounds should be more specific than direct 
cannabinoid agonists since they primarily affect endocannabinoid levels and hence the state of 
activation of cannabinoid receptors not in all tissues expressing functionally active 
cannabinoid receptors but only in those where these compounds are produced on demand. So, 
by this strategy the psychotropic and immunosuppressive side effects which limit the use of 
cannabinoid based drugs could be reduced.  
Combination therapies utilizing both - molecules targeting the endocannabinoid system and 
natural anticancer agents or benchmark chemotherapeutic agents- are a worthwhile option to 
be further systematically explored in the treatment of cancer. 
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